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ABSTRACT
Liver fibrosis is a pathological condition characterized by the excessive
deposition of extracellular matrix material by activated hepatic stellate cells (HSCs). We
recently reported that activation of the aryl hydrocarbon receptor (AhR), a ligandactivated transcription factor, with 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) increases
HSC activation in vitro and in mouse models of experimental liver fibrosis. The goal of
this project was to determine the mechanism by which AhR activation impacts HSC
activation and the subsequent development of liver fibrosis. It is possible that HSCs are
direct cellular targets for TCDD. Alternatively, TCDD could increase HSC activation
indirectly by exacerbating hepatocyte damage and inflammation. To investigate this, we
generated mice in which the AhR was selectively removed from either hepatocytes or
HSCs to determine the ramifications on liver injury, inflammation, and HSC activation in
an experimental model of liver fibrosis elicited by chronic administration of TCDD.
Results from these studies indicate that TCDD does not directly activate HSCs in the
mouse liver to produce fibrosis. Instead, it appears that TCDD-induced changes in
hepatocytes, such as the development of steatosis, are what ultimately stimulate HSC
activation and produce fibrosis. A second focus of this project was to investigate an
endogenous role for AhR signaling in the regulation of HSC activation in the absence of
liver injury and inflammation. To this end, I used CRISPR/Cas9 technology to knock
down the AhR in the human HSC cell line, LX-2. I discovered that a functional AhR is
required for optimal proliferation of activated HSCs. However, other endpoints of HSC
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activation, such as the production of collagen type I, were not impacted by the removal of
AhR signaling. These findings are important because the AhR has been shown to be a
druggable target, and there is growing interest in therapeutically modulating AhR activity
to prevent or reverse HSC activation. Collectively, results from this project indicate that
therapeutically targeting AhR signaling in hepatocytes, instead of AhR signaling in
HSCs, might be a preferred approach for limiting HSC activation and preventing or
diminishing liver fibrosis.
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CHAPTER ONE: INTRODUCTION
Halogenated Aromatic Hydrocarbons
Halogenated aromatic hydrocarbons (HAHs) are widespread and persistent
environmental pollutants that include dioxins, furans, and biphenyls (Poland and
Knutson, 1982). These chemicals share a similar chemical structure, which includes a
benzene ring and one or more atoms of a halogen (Figure 1.1). Because HAHs are
lipophilic, they partition into the fatty tissue of living organisms, where they
bioaccumulate (Birnbaum, 1985). Most humans accumulate these chemicals over a
lifetime through the consumption of fish, meat, poultry, and dairy products.
Within the HAH family of chemicals, the polychlorinated biphenyls (PCBs),
dioxins, and furans are of particular concern because they are further classified as
persistent organic pollutants (POPs). POPs are a global concern because of their ability to
persist in the environment, be transported long distances, bioaccumulate in the food
chain, and adversely affect human health and the environment. In 2001, an international
environmental treaty was signed to eliminate or restrict the production and use of POPs.
This treaty, which was called the Stockholm Convention on Persistent Organic
Pollutants, originally identified twelve POPs of particular concern, and these chemicals
are referred to as the “Dirty Dozen.” Three of the 12 chemicals on this list are members
of the HAH family: PCBs, polychlorinated dibenzo-p-dioxins (PCDDs), and
polychlorinated dibenzofurans (PCDFs).
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Figure 1.1

Structures of HAHs

PCBs
PCBs were once widely produced for industrial use as heat exchange fluids, in
electric transformers and capacitors, and as additives in paint, carbonless copy paper, and
plastics (Erickson and Kaley, 2011). These chemicals were heavily manufactured until
being banned in the U.S. in 1979, and the use of PCBs in equipment is scheduled to be
phased out by 2025 (Robertson et al., 2018). However, PCBs are still released into the
environment from the disposal of large-scale electrical equipment and waste, and these
chemicals continue to pose a human health concern due to their persistence in the
environment.
There are 209 different possible congeners within the PCB family, and the degree
of toxicity of each congener depends on its chlorination pattern. The most toxic PCB
congeners have their two phenyl rings in the same plane with no chlorine atoms in the
ortho position. Compared to non-coplanar PCBs, these coplanar (or “non-ortho”) PCBs
are more stable in the environment, more resistant to degradation, and capable of
producing greater toxicity. Coplanar PCBs are also called “dioxin-like” PCBs because
they are structurally similar to dioxins and share a common mechanism of action, which
involves binding to the aryl hydrocarbon receptor (AhR). Of the 209 PCB congeners, 12
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have been classified as dioxin-like compounds and are the focus of concern from an
environmental and public health standpoint.
PCDDs and PCDFs
The other two HAHs on the Dirty Dozen list are the PCDDs and PCDFs. Both of
these compounds have never been intentionally produced. Instead, they are typically
produced unintentionally, either through incomplete combustion or during the
manufacturing of chlorine-based herbicides and pesticides. Dioxins, in particular, have
been associated with numerous adverse effects in humans and laboratory animals. Furans
are produced through the same processes that produce dioxins, and also during the
production of PCBs.
The basic chemical structure of all dioxins consists of two benzene rings, which
are connected by one or two oxygen atoms, and 4-8 chlorine atoms as substituents. Based
on the position of the chlorine atoms, there are 75 possible dioxin congeners (reviewed in
Schecter et al., 2006). The World Health Organization classified 7 PCDDs as dioxins that
are of concern to the environment (WHO, 2010). This classification was performed
based on the toxic potency of each chemical relative to 2,3,7,8-tetrachlorodibenzo-pdioxin (TCDD) (Berg et al., 2006). TCDD is the most toxic dioxin due to the pattern of
chlorine substitutions at positions 2, 3, 7, and 8 on the benzene rings (Figure 1.2).
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2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
TCDD is a persistent environmental pollutant with a half-life of 10-100 years in
soil (Seike et al., 2007). Degradation of TCDD occurs primarily by photolysis via
ultraviolet exposure, which splits the chlorine atoms off of TCDD. The half-life of TCDD
is 11 days in mice and 23.7 days in rats and rabbits (Ryan et al., 1990). In humans, the
half-life of TCDD is reported to be 1-2 years (Sorg et al., 2009). TCDD is a potent
inducer of the gene encoding the xenobiotic metabolizing enzyme, cytochrome P4501A1,
as well as several other enzymes involved in phase I and phase II metabolism (Nebert,
Puga and Vasiliou, 1993). However, TCDD itself is not a substrate for cytochrome
P4501A1, due to steric hindrance at the enzyme active site (Dutkiewicz and Mikstacka,
2018). As a result, TCDD is not metabolized, which contributes to its long half-life
compared to other environmental contaminants, including other HAHs (Ryan et al.,1990).

Figure 1.2

Structure of 2, 3, 7,8-Tetrachlorodibenzo-p-dioxin (TCDD)

TCDD Sources and Exposure
There are both natural and human-made sources of TCDD. Natural sources of
TCDD include volcanoes and forest fires. TCDD is also produced as an unintentional
byproduct of herbicide manufacturing and the chlorine bleaching of paper. TCDD gained
notoriety when it was found to have been released as an unintended contaminant of Agent
Orange, which was an herbicide that was sprayed during the Vietnam War from the early
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1960s to the early 1970s. Currently, the most prominent source of TCDD in the
environment is the burning of waste products such as chlorine-based plastics, and
household and municipal waste, which primarily results in dioxin formation within the
temperature range of 200-450°C (Z, 2018). Once formed, TCDD is released into the
environment either in an aerosol state, which is adsorbed onto dust particles, or liquid
state, which deposits into water or onto land. From any of these sources, TCDD may then
reach plants and animals and bioaccumulate. The primary source of human exposure to
TCDD is through dietary consumption. For example, TCDD- contaminated animal feed
led to the contamination of pork products from Ireland in 2008 (Tlustos et. al., 2011).
Another example is the disposal of TCDD-contaminated industrial oil, which resulted in
contamination of animal feed and animal-based food products from Belgium in 1999
(Bernard and Fierens 2002). However, human exposure can also occur through accidental
and occupational exposures (Pelclova et al., 2006). In fact, one of the worst industrial
accidents in the world occurred in 1976, when a chemical plant explosion exposed
residents in Seveso, Italy, to high levels of TCDD (Eskenazi et al., 2018). Hence, TCDD
and related dioxins pose a public health issue, as humans can potentially be exposed to
these chemicals through environmental and accidental exposure.
TCDD Toxicity in Humans
The consequences of TCDD exposure in humans have largely been identified
based on analyzing longitudinal health data of people exposed accidentally to TCDD. In
humans that were exposed during the chemical plant explosion in Seveso, Italy, one of
the most prevalent toxic effects of TCDD was chloracne, which is characterized by skin
eruption of blackheads, cysts, and nodules (Reggiani, 1980). Several studies also revealed
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an increased risk for type 2 diabetes with dioxin exposure (Kim et al. 2003; Kogevinas
2001; Remillard and Bunce, 2002). Additional toxic effects of TCDD that have been
reported include atherosclerosis, neuropsychological impairment, and ocular vascular
changes after decades of exposure (Kim et al., 2003; Pelclova et al., 2006). In addition,
railroad workers exposed to TCDD showed dystonia and peripheral neuropathy
(Klawans, 1987).
TCDD is classified as a “known human carcinogen” by the International Agency for
Research on Cancer (Cole et al., 2003). Available data from workers at Dow Chemical,
where TCDD was produced, indicate that chronic exposure to TCDD increased the risk
for cancer (Kogevinas, 2001). Furthermore, increased risk of prostate cancer was
identified in U.S. Air Force veterans who served in the Vietnam War in Operation Ranch
Hand, which was the operation in which Agent Orange was sprayed (Pavuk, Michalek
and Ketchum, 2006).
The Aryl Hydrocarbon Receptor (AhR)
TCDD and other HAHs exert their toxic effects through interaction with a
soluble, cytoplasmic protein called the aryl hydrocarbon receptor (AhR) (FernandezSalguero et al., 1996). The AhR is a transcription factor that belongs to the basic helixloop-helix-Per-ARNT-Sim family (bHLH-PAS). As shown in Figure 1.3, the amino
terminus of the AhR protein contains bHLH motifs that function in DNA binding
(Fukunaga and Hankinson, 1996). Next to the bHLH domain is the PAS domain, which
contains a conserved domain of 250-300 amino acids. The PAS domain shares sequence
similarity with three eukaryotic proteins: the period circadian protein (Per), the vertebrate
AhR nuclear translocator (ARNT), and a Drosophila protein involved in embryonic
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development called single-minded (Sim) (Burbach et al., 1992). The PAS domain also
contains binding sites for two molecules of heat shock 90 (Hsp90) protein, which are
molecular chaperones (Antonsson et al. 1995; Fukunaga et al. 1995). The PAS domain is
comprised of two subdomains, PAS-A and PAS-B, each of which contains about 50
amino acids. The PAS-B subdomain contains a ligand-binding domain that allows the
AhR to interact with ligands (Coumailleau et al. 1995). In fact, the AhR is the only
protein in the bHLH/PAS family that functions as a receptor (Coumailleau et al., 1995).
The carboxy-terminus contains highly variable amino acids that make up a transcription
activation domain and determines the cellular localization of the AhR (Coumailleau et
al., 1995).

Figure 1.3

Functional Domains of the AhR

The domains that are common to proteins in the bHLH/PAS family are represented.
Hsp90, heat shock protein-90.

Mechanism of AhR Activation
Vertebrates have evolved to defend against exposure to toxic compounds
encountered in the environment and produced within the body as byproducts of
enzymatic reactions. The AhR appears to mediate dynamic responses to both
environmentally and endogenously generated toxins, and this led researchers to consider
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the wide-ranging roles of AhR. Understanding the molecular mechanisms of AhR
activation is crucial for elucidating the broad functions of this protein.
In the absence of ligand, the AhR is found in the cytoplasm, where it forms a
complex with Hsp90 (Denis et al., 1988), AhR interacting protein (AIP; also called Xassociated protein-2) (Ma and Whitlock, 1997; Meyer et al., 1998), and a 23-kDa protein
(p23) (Cox and Miller, 2004). Also, the tyrosine kinase c-src has been reported as an
integral component of the cytosolic AhR complex (Enan and Matsumura, 1996). Hsp90
has roles in localizing AhR in the cytoplasm and preventing its degradation (Pongratz,
Mason and Poellinger, 1992; Bell and Poland, 2000). AIP protects the AhR from
ubiquitination-mediated degradation (Kazlauskas, Poellinger and Pongratz, 2000), and
p23 helps stabilize the AhR-Hsp90 interaction (Cox and Miller, 2004). Hsp90 masks the
ligand-binding site and nuclear localization sequence (NLS) in the bHLH domain of the
AhR (Pongratz, Mason and Poellinger, 1992). Upon ligand binding at the PAS-B domain,
the AhR undergoes a conformational change that releases these cofactors (Wilhelmsson
et al., 1990; Ikuta et al., 1998). As a result, the NLS and DNA-binding domains are
revealed, and the AhR translocates to the nucleus (Pollenz, Sattler and Poland, 1994).
This “classical” mechanism of AhR activation is shown in Figure 1.4.
Once inside the nucleus, the AhR binds with ARNT and forms a heterodimeric
transcriptional complex. The heterodimerization happens through the interaction of the
bHLH and PAS domains of both proteins (Probst et al., 1993). The AhR/ARNT complex
then binds to cognate DNA sequences termed xenobiotic response elements (XREs), also
known as dioxin-responsive elements (DRE), through the bHLH domain (Ko et al.,
1997). The XRE motif contains the core bases 5'-GCGTG-3'. Gene that contain XREs in
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the promoter and/or enhancer regions and are responsive to AhR activation are said to be
AhR-regulated genes.
Binding of the AhR/ARNT complex to DNA leads to the physical interaction of
the complex with several co-activator proteins that relax the chromatin structure and
recruit the transcription machinery. The AhR contains several modular domains: an
acidic region, a glutamine-rich region, and a region rich in proline/serine/threonine
residues. The ARNT protein possesses domains of glutamine-rich region and
proline/serine/threonine residues (Jain et al., 1994). These domains interact with different
cofactors to serve different functions. Upon DNA binding, the AhR/ARNT complex
recruits several transcriptional co-activator proteins, including CBP/p300 (Kobayashi et
al., 1997), SRC-1 (Kumar and Perdew, 1999), NCoA2/GRIP1/TIF2, p/CIP, RIP140
(Beischlag et al., 2002), and Brg-1 (Wang and Hankinson, 2002). The AhR/ARNT
complex can also directly interact with transcription factors, such as TFIIB, TFIID/TBP,
and TFIIF (Rowlands, Mcewan and Gustafsson, 1996; Swanson and Yang, 1998). This
interaction occurred through the AhR/ARNT complex, while either AhR or ARNT alone
were insufficient for this the interaction.
Exposure to TCDD modulates the expression of many genes through an AhRdependent mechanism. Nevertheless, many of these genes lack a clearly defined XRE.
Recent studies have identified a novel non-consensus XRE (NC-XRE) in the promoter of
the gene encoding plasminogen activator inhibitor-1 (PAI-1), which is known to be
regulated by AhR activation (Huang and Elferink, 2012). Interestingly, chromatin
immunoprecipitation and RNA interference studies showed that ARNT is not a
component of the NC-XRE-bound AhR complex. Subsequent studies on the NC-XRE-
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bound AhR complex revealed many novel Krüppel-like factor (KLF) protein family as
AhR binding partners (Wilson, et al., 2013). The AhR has also been shown to bind to the
NF-kB subunit, RelA, to induce expression of interleukin-6 (IL-6) and c-myc (Kim et al.,
2000). These studies underscore the complexity of AhR transcriptional activity.
Termination of AhR Signaling
Termination of AhR signaling following transcriptional activation is required to
prevent long-lasting gene modulation. Termination of AhR activity is largely achieved
through proteasomal degradation. Proteasomal degradation is accomplished by
transporting the AhR back to the cytoplasm through the recognition of a nuclear export
signal by the CRM-1 protein (Davarinos and Pollenz, 1999). In the cytoplasm, the
receptor undergoes ubiquitination and is subsequently degraded by the 26S proteasome
(Ma, Baldwin and Virginia, 2000). In addition, the AhR protein itself was found to be a
ligand-dependent E3 ubiquitin ligase, capable of targeting sex steroid hormone receptors
for degradation (Ohtake et al., 2007). Another regulatory mechanism for termination of
AhR activity is through competitive inhibition by a protein called the AhR repressor. This
protein shares structural similarities with the N-terminus of the AhR, which makes it
possible for the repressor to compete with ARNT for dimerization with the AhR (Mimura
et al., 1999).
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Figure 1.4

Classical Mechanism of AhR Activation

Binding of exogenous or endogenous ligands to the AhR causes the dissociation of
cofactors, resulting in nuclear translocation of the AhR. In the nucleus, the AhR
heterodimerizes with the AhR nuclear translocator (ARNT). The AhR-ARNT-ligand
complex modulates gene transcription by binding to xenobiotic response elements
(XREs).
AhR Ligands
The AhR is activated by structurally diverse ligands, including endogenous,
exogenous, and dietary ligands. Endogenous ligands are those compounds and
metabolites that are formed within a biological system. In contrast, exogenous AhR
ligands are typically produced through anthropogenic activities. Some of these ligands
are further discussed below.
Exogenous AhR Ligands
As previously discussed, exogenous AhR ligands include HAHs, such as dioxins
(e.g., TCDD), furans, and polychlorinated biphenyls. Another family of exogenous AhR
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ligands is polycyclic aromatic hydrocarbons (PAHs), which include the human
carcinogen benzo[a]pyrene, as well as 3-methylcholanthrene and benzoflavones (Denison
et al., 2002). PAHs are primarily generated during the incomplete combustion of organic
material, such as coal, wood, oil, and petrol (reviewed in Abdel-Shafy and Mansour,
2016). The carcinogenicity of PAHs has been well established, with benzo[a]pyrene
having been classified as a “known animal carcinogen” by the U.S. Department of Health
and Human Services and “probably carcinogenic to humans” by the International Agency
for Research on Cancer (IARC) (International Agency for Research on Cancer, 2016). In
contrast to TCDD, PAHs are extensively metabolized by the cytochrome P450-mediated
oxidase system (reviewed in Abdel-Shafy and Mansour, 2016). The induction of phase I
enzymes by PAHs is AhR-dependent, and these enzymes are responsible for the
metabolic activation of the parent PAH compound, resulting in the production of
mutagenic metabolites, DNA adduct formation, and carcinogenesis (Kondraganti et al.,
2003).
Endogenous AhR Ligands
The AhR was originally identified as a transcription factor that mediated the toxic
effects of environmental toxicants, but the endogenous ligand for this receptor, as well as
its physiological role, was unknown. Studies with AhR knockout mice demonstrated that
the AhR likely played a physiological role in liver development. This was evident based
on reports of reduced liver size in two different strains of AhR-null mice (FernandezSalguero et al., 1996; Schmidt et al., 1996). The AhR is also required for closure of the
ductus venosus, which is an intrahepatic shunt in the fetal liver (Lahvis and Bradfield
1998). Finally, AhR-null mice displayed portal fibrosis, hypercellularity, impaired
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retinoic acid catabolism (Schmidt et al., 1996; Gonzalez and Fernandez-Salguero, 1998).
It has been proposed that these abnormal phenotypic changes result from the absence of
endogenous AhR activity, which results in unchecked levels of endogenously generated
toxins (Fernandez-Salguero et al., 1995; Lahvis and Bradfield, 1998). However, the
molecule mechanisms and physiological ramifications of endogenous AhR activation are
still under investigation.
Most of the endogenous ligands are byproducts of normal biochemical reactions
in a cell and are classified into structurally distinct classes of chemicals. Many of the
endogenous AhR ligands identified demonstrate a weak affinity for AhR binding when
compared to TCDD. AhR endogenous ligands can be classified as indoles, tetrapyrroles,
arachidonic acid metabolites, and other ligands. As shown in Figure 1.5, these
endogenous ligands are structurally diverse. Some of the endogenous ligands are
discussed below.
Indoles
Several in vivo and in vitro studies indicate that indole-containing chemicals can
activate the AhR. For example, AhR activation by ultraviolet photoproducts of
tryptophan and histidine was reported (Helferich and Denison, 1991). Tryptophan, and
naturally occurring tryptophan metabolites, such as tryptamine and indole acetic acid, can
induce AhR-dependent gene expression, suggesting that these metabolites may also be
metabolized by cytochrome P450 enzymes (Heath-Pagliuso et al., 1998). Indirubin and
indigo, which are found in human urine, are another group of endogenous, indolecontaining chemicals that have been shown to activate the AhR (Adachi et al., 2001).
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Figure 1.5

Structures of Endogenous AhR Ligands

Another chemical in the indole family, 2-(1'H-indole-3'carbonyl)-thiazole-4carboxylic acid methyl ester (ITE), was recently reported to be a potent endogenous AhR
ligand (Henry et al., 2006). ITE is a tryptophan metabolite with 6 times less AhR binding
affinity than TCDD (Ki values for ITE and TCDD are 3 nM and 0.5 nM, respectively)
(Figure 1.6) (Song et al., 2002). ITE has been reported to induce a gene expression
profile that is remarkably similar to that induced by TCDD , including the induction of
AhR-dependent xenobiotic-metabolizing enzymes (Henry, Welle and Gasiewicz, 2009).
However, ITE did not produce any dioxin-like toxicity (Ehrlich and Kerkvliet, 2017). It
has also been reported that AhR levels, which are rapidly degraded in response to
agonist-induced activation, were partially restored within 24 h after ITE treatment, but
not 24 h after TCDD treatment (Henry et al., 2009). This supports the notion that ITE is
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readily metabolized, unlike TCDD. However, the molecular mechanism of ITE clearance
is largely unknown. Rapid clearance and lack of toxicity make ITE a potential therapeutic
AhR agonist.

Figure 1.6

Chemical Structure of 2-(1'H-indole-3'carbonyl)-Thiazole4-Carboxylic Acid Methyl Ester (ITE)

Tetrapyrroles
It has been reported that exogenously added hemin, biliverdin, or bilirubin induce
the expression of CYP1A1 and other XRE-dependent genes in mouse hepatoma
Hepa1c1c7 cells (Sinal and Bend, 1997). CYP1A1 is the gene that encodes cytochrome
P4501A1, and its expression is considered a hallmark of AhR activation. Subsequent
studies showed that mRNA and protein levels of CYP1A1 and CYP1A2 were elevated in
congenitally jaundiced Gunn rats, which exhibit high plasma bilirubin levels due to
impaired bilirubin conjugation (Kapitulnik and Gonzalez, 1993). These results support
the notion that bilirubin and biliverdin are endogenous AhR ligands.
Arachidonic Acid Metabolites
TCDD is known to increase the release of arachidonic acid (AA) from the cell
membrane by stimulating lipid oxidation and activating phospholipases (Denison and
Nagy, 2003). Lipoxin A4, which is a lipoxygenase product of AA, can up-regulate the
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expression of CYP1A1 in an AhR-dependent reporter assay (Nagy et al., 2002). These
findings suggest that AA metabolites are yet another class of endogenous AhR ligands.
Dietary AhR Ligands
A variety of naturally occurring, plant-derived materials have been shown to
induce AhR activation. The several nutritional plant compounds such as
dibenzoylmethanes, (MacDonald et al., 2001) curcumin, (Ciolino et al., 1998) can
activate AhR. The carotenoids such as β-carotene (bC), bixin (BX), lycopene, lutein,
canthaxanthin, and astaxanthin (AX) competitively bind to AhR (Jewell and O’Brien,
1999). Possibly the plants-derived materials are the largest class of natural AhR ligands
to which humans and animals are exposed.
TCDD Toxicity in Rodents
Most of our knowledge about TCDD toxicity is derived from studies in which
TCDD was administered to rodents. In mice, the dose of TCDD required to produce
death in 50% of animals (lethal dose-50, LD50) is 182 to 2570 µg/kg body weight, when
administered orally (Chapman and Schiller, 1985). This wide range of concentration
reflects the fact that some strains of mice express the ‘b’ allele of the AhR gene, which
encodes an AhR protein with high affinity for ligand, compared to other strains that
express the low-affinity ‘d’ allele (Chang et al., 1993). Mice exposed to TCDD exhibited
dose-related endpoints. Toxic endpoints observed at low doses of TCDD (2.4-500 ng/kg)
include disturbed steroid secretion and impaired cochlear function (Baldridge et al., 2015,
Safe and Luebke, 2016). Effects seen at moderate doses of TCDD (0.2-30 µg/kg ) include
decreased thymus and spleen size, hepatomegaly, lipid accumulation, inflammation,
immunosuppression, and carcinogenicity (Vos, Moore, and Zinkl, 1974; Van Miller,
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Lalich and Allen, 1977; Poland and Glover, 1980). Finally, high doses of TCDD (>200
µg/kg) produced hypophagia, beta cell apoptosis, and death (Hoyeck et al., 2020). These
dose-dependent endpoints also varied according to species, gender, administration route,
and the number of doses.
TCDD Hepatotoxicity
The liver is a target organ for TCDD-induced toxicity. The liver consists
primarily of parenchymal cells called hepatocytes (80%), as well as non-parenchymal
cells, including hepatic stellate cells (HSCs), sinusoidal endothelial cells, stellate cells,
and Kupffer cells. The AhR is expressed in all liver cells and is highly expressed in
hepatocytes. In fact, the majority of TCDD hepatotoxicity studies have focused on
hepatocytes, and less is known about the ramifications of AhR signaling in nonparenchymal cell populations. In rodents, TCDD hepatotoxicity includes various
endpoints, including hepatomegaly, hepatocyte necrosis and apoptosis, inflammation, fat
accumulation, dysregulation of vitamin A homeostasis, and fibrosis. These endpoints are
discussed in further detail below.
Hepatocyte Necrosis
TCDD has been shown to produce mild or moderate necrosis in the liver (Flower et al.,
1973; Jones and Butler 1974). The presence of necrosis is further corroborated by the
elevation of levels of alanine aminotransferase (ALT) enzymes in the serum and plasma
(Pohjanvirta and Tuomisto, 1994). However, the effects of TCDD on hepatocyte
apoptosis are less clear-cut and vary depending on the model system.
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Steatosis
Steatosis (fatty liver) refers to intrahepatic fat accumulation that comprises at least
5% of the overall liver weight. Steatosis is also referred to as nonalcoholic fatty liver
(NAFL). Steatosis can be seen as macrovesicular steatosis (large droplets) or
microvesicular steatosis (small droplets). The liver is a critical organ for fat metabolism.
TCDD exposure is shown to disturb liver function by altering fatty acid and triglyceride
metabolism. In mice, TCDD altered hepatic gene expression related to lipid transport,
partitioning, and metabolism (Kopec et al., 2011). If left untreated, NAFL can progress
towards a more aggressive form of liver disease called nonalcoholic steatohepatitis
(NASH). In NASH, fat accumulation is associated with inflammation and fibrosis
(scarring), which can lead to cirrhosis, hepatocellular carcinoma, or death.
Vitamin A Dysregulation
About 80% of the vitamin A in the body is stored in HSCs as retinol. Both
endogenous and exogenous AhR activation adversely affects vitamin A homeostasis. For
example, TCDD exposure has been shown to reduce vitamin A levels (Thunberg et al.,
1980; Pohjanvirta et al., 1990; Hakansson et al., 1991). There is evidence to suggest a
positive correlation between TCDD-induced liver toxicity and decreased vitamin A stores
(Pohjanvirta et al., 1990; Fletcher, Hanberg and Håkansson, 2001). This is corroborated
by a study that showed that injection of exogenous vitamin A reduced TCDD-induced
body wasting, hepatomegaly, thymic atrophy, production of reactive oxygen species, and
DNA damage (Alsharif and Hassoun, 2004). A more recent study from our lab also
showed that TCDD inhibits lipid storage droplets in human hepatic stellate cells, LX-2
(Harvey et al., 2016). These data suggest the importance of vitamin A homeostasis in
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liver toxicity. Hence, it is important to study the consequences of AhR signaling in HSC
activation.
Inflammation
Chronic hepatic inflammation is one of the common triggers and characteristics of
liver disease. Both acute and chronic exposure to TCDD have been reported to alter the
expression of inflammatory cytokines in the liver, including IL-1α, IL-1β, TNF-α , IL-6,
and monocyte chemoattractant protein-1 (MCP-1) (Olivero-Verbel, Roth and Ganey,
2011; Ozeki et al., 2011; Del-Campo et al., 2018). Increased production of MCP-1 can
attract neutrophils and monocytes, which can exacerbate inflammation. However, the
mechanism by which this occurs, and which liver cell populations are directly impacted
by TCDD treatment, remain unclear. Understanding how AhR signaling in diverse cell
populations impacts inflammation is important for understanding the interplay within
different liver cells, which is a subject addressed in this dissertation.
Hepatocellular Carcinoma
The carcinogenic effects of TCDD have been studied for the past five decades
with results obtained from a variety of tissues. In rats, chronic administration of TCDD at
doses as low as 0.001 µg/kg/week for 78 weeks induced cancerous tumors in various
tissues including tear ducts, kidneys, skin, testes, brains, skeletal muscles, lungs and
livers (Van Miller, Lalich and Allen, 1977). Mice treated with TCDD at 0.05 µg/kg/week
for two years developed liver cancer and thyroid adenomas (National Toxicology
Program, 1982). Male mice gavaged with 10 µg/kg every two weeks for 24 weeks
developed tumors in the liver (Kennedy et al., 2014). Results from these animal studies
indicate that TCCD is a potent carcinogen. There is no evidence to indicate that TCDD is
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mutagenic, as it does not appear to bind or to damage DNA (Huff et al., 1980; Pitot et al.,
1980). Instead, TCDD is classified as a tumor promoter (Knerr and Schrenh 2006). In the
liver, TCDD appears to elicit tumorigenesis by altering hepatocyte proliferation and
apoptosis. However, studies with AhR-deficient mice suggest that the AhR functions as a
suppressor of liver carcinogenesis, possibly through endogenous activation (Fan et al.,
2010).
Modulation of Hepatocyte Proliferation
TCDD was shown to decrease the proliferation of primary hepatocyte cells from
rats by suppressing DNA synthesis (Hushka and Greenlee, 1995). TCDD suppressed
hepatocyte proliferation in livers of rodents that had been subjected to a partial
hepatectomy (Bauman et al., 1995). Another study reported that TCDD treatment shunted
regeneration by reducing cyclin-dependent kinase-2 (CDK2) activity, a pivotal regulator
of the G1/S phase transition (Mitchell et al., 2006). TCDD can also induce AhR
heterodimerization to E2F transcription factors, thereby repressing the expression of
genes required for S-phase progression in the cell cycle (Puga et al., 2000; Elferink,
2003). TCDD treatment suppressed hepatocyte proliferation through induction in
p21Cip1 and p27Kip expression, which are negative regulators of proliferation (Kolluri et
al., 1999; Jackson et al., 2014). However, in contrast to these studies, prolonged TCDD
treatment for 30 weeks was found to increase hepatic cell proliferation (Lucier et al.,
1991; Tritscher et al., 1995). These inconsistencies highlight the possibility of multiple
mechanisms by which TCDD modulates proliferation.
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Fibrosis
Fibrosis is an aberrant wound-healing process characterized by the excessive
deposition of extracellular matrix (ECM) material, mainly collagen (Brenner et al.,
2000). The onset of fibrotic progression can be triggered by chronic injury and
inflammation (Wynn, 2008). Accumulating evidence suggests a role for AhR signaling in
liver fibrosis. For instance, exposure of mice to TCDD for 2 weeks elicited hepatic
expression of collagen type I and markers of liver fibrosis (Pierre et al., 2014). These
effects were not observed in AhR knockout mice (Pierre et al., 2014). A recent study
reported that chronic administration of TCDD increased collagen accumulation in the
mouse liver (Nault et al., 2016). In addition, examination of the liver of AhR-null mice
revealed the presence of fibrotic lesions despite the absence of any exogenous agonist,
such as TCDD (Fernandez-Salguero et al., 1995). This raises the intriguing possibility
that endogenous AhR signaling may be important for repressing HSC activation and
preventing the development of liver fibrosis.
Liver Fibrosis
In 2017, liver disease was the 12th leading cause of death in the United States,
according to the World Health Organization. The major cause of mortality and morbidity
associated with liver disease is liver cirrhosis and hepatocellular carcinoma, both of
which represent advanced stages of liver disease. Liver fibrosis is characterized by an
abnormal accumulation of ECM material due to increased deposition and/or reduced
degradation of collagen fibers. Currently, no drugs have been approved by the Food and
Drug Administration to prevent or reverse liver fibrosis. There is an urgent need to
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understand the molecular mechanisms of liver fibrosis and the progression of liver
disease and to identify novel therapeutic targets for treating this disease.
Liver fibrosis can be caused by a range of insults, including toxins, alcohol,
hepatitis C virus infection (HCV), and drug-induced liver injury (DILI). The prevalence
of HCV-induced liver fibrosis is increasing, especially in people 60 years old and above.
DILI can develop following abuse of medications such as over-the-counter drugs (Lee,
2003). There are no risk factors identified for DILI, but certain individuals with genetic
susceptibility and pre-existing liver disease may be particularly susceptible to DILI onset
(Donepudi et al., 2012). The incidence and prevalence of liver fibrosis are increasing due
to confounding factors, which include type 2 diabetes, obesity, and NAFL. Type 2
diabetes and NAFL, in particular, are common causes of liver fibrosis and often coexist
in patients with fibrosis (Anstee, McPherson, and Day, 2011). In fact, a recent analysis of
827 patients with advanced liver fibrosis indicates that most patients also suffer from
obesity and insulin resistance (Harrison et al., 2008).
Liver Injury and Inflammation
As discussed earlier, injury and inflammation are important triggers for liver
fibrosis. Liver injury can be either acute or chronic. Acute liver injury is characterized by
transient fibrogenesis, which lasts for days to a few weeks, and from which the injured
liver tissue can recover almost completely. In contrast, during chronic liver injury, the
collagen content in the liver increases. In advanced stages of fibrosis, the liver develops
nodules that can hinder blood flow, which produces areas of regeneration throughout the
liver that exists as nodules. This condition is referred to as cirrhosis, and it can eventually
progress to hepatocellular carcinoma (Suk and Kim, 2015). The term "liver injury”
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includes hepatocyte necrosis and apoptosis, steatosis, and steatohepatitis. Furthermore,
inflammatory cells, such as activated Kupffer cells, which are resident macrophages, are
reported to participate in liver injury and fibrogenesis by producing transforming growth
factor-beta-1 (TGFβ1), which is the major driver of fibrogenesis (Norona et al., 2019).
Taken together, multiple pathways of liver injury and inflammation can contribute to the
development of liver fibrosis.
Liver Fibrosis Reversal
Recent reports suggest that the reversibility of liver fibrosis is achievable.
Accumulating evidence was documented in liver fibrosis reversal across different
etiologies, including viral hepatitis, autoimmune hepatitis, and NASH (Dixon et al.,
2004; Brenner, 2013). Patients successfully treated for HCV showed no evidence of
fibrosis upon HCV recovery, and this was confirmed by repeated biopsy (Brenner, 2013).
However, the reversal of fibrosis is not possible at all advanced stages of fibrosis. In fact,
patients with advanced cirrhosis failed to recover. This raises the possibility that there is a
“point of no return” in liver fibrosis progression. Possibly the point of recovery is
dependent on the amount of ECM remodeling that has occurred.
Extracellular Matrix
The extracellular matrix (ECM) is a dynamic component in the liver. In a healthy
liver, the ECM helps maintain tissue homeostasis. In the injured liver, ECM remodeling
favors the excess accumulation of ECM, predominantly collagen type I, along with
fibronectin and laminin (Martinez-Hernandez, Delgado, and Amenta, 1991). During
chronic liver disease, dysregulation of ECM metabolism can result in hepatic collagen
levels that are eight-fold higher than those observed in the healthy liver (Wells, 2008).
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Hepatic Stellate Cells
HSC are central mediators of liver fibrosis. In a healthy liver, HSCs primarily
function in storing vitamin A, but they are also involved in retinoic acid homeostasis,
vasoregulation through endothelial cell interactions, extracellular matrix homeostasis,
drug detoxification, and immunotolerance (Senoo, 2004; Puche, Saiman and Friedman,
2013). Upon liver injury, HSCs become activated and assume a myofibroblast-like
phenotype, characterized by increased proliferation, contractility, fibrogenesis, and
retinoid loss (Li et al., 2008). HSC activation is a complex phenomenon involving many
pathways, cells, and events.
TCDD and Liver Fibrosis
The role of AhR signaling in liver fibrosis is an emerging area of research. There
is evidence to indicate a role for endogenous AhR signaling in repressing fibrogenesis.
For example, AhR-knockout (AhR-KO) mice have livers that are reduced in size by 50
percent and show bile duct fibrosis (Fernandez-Salguero et al., 1995). The livers of AhRKO mice also have collagen content that is 53% greater than the liver of wildtype mice
(Peterson et al., 2000). Whereas endogenous AhR activity appears to suppress fibrosis,
exogenous AhR activation with TCDD promotes it. For example, it was recently found
that, in wild-type mice that express a functional AhR, chronic TCDD treatment elicited
liver fibrosis through an AhR-dependent manner (Pierre et al., 2014). It is possible that
treating with TCDD promotes fibrosis by preventing endogenous receptor activation,
essentially resulting in de-repression of fibrogenesis. Using an AhR-KO model system in
mice is not ideal for studying liver fibrosis as half of the pups were reported to have died
postnatally, and the survivors exhibited diminished fertility (Fernandez-Salguero et al.,
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1995). This project sought to investigate how AhR signaling impacts fibrosis using mice
in which the AhR was selectively removed from different cell populations in the liver.
The use of experimental animal models is vital for understanding liver fibrosis.
As discussed earlier, excess collagen deposition by HSCs can be triggered by multiple
mechanisms. Each experimental model system can induce liver fibrosis through a
different mechanism. Some of the widely used experimental models are discussed below.
Chronic Administration of Carbon Tetrachloride
Carbon tetrachloride (CCl4) has been widely used to experimentally induce both
acute and chronic liver injury. CCl4 administration induces expression of Cyp2e1, which
is the gene that encodes the xenobiotic metabolizing enzyme, cytochrome P450E1. This
enzyme metabolizes CCl4 into a trichloromethyl radical, which produces liver injury by
eliciting lipid peroxidation in the cell membrane (Wong, Chan and Lee, 1998). CCl4induced liver injury is characterized by centrilobular necrosis, which is followed by
fibrosis (Yu et al., 2002). In fact, chronic administration of CCl4 is a well-established
model of experimental liver fibrosis (reviewed in Delire et al., 2015). Our lab recently
used this model to show that AhR activation by TCDD increased necroinflammation and
HSC activation in the CCl4-injured mouse liver (Lamb et al., 2016a; Lamb et al., 2016b).
This suggests that exogenous AhR activation can exacerbate the fibrogenic response to
injury.
Bile Duct Ligation
Bile duct ligation (BDL) is another classic model of experimental liver fibrosis, in
which cholestatic injury drives the development of periportal biliary fibrosis. In this
model, the bile duct is ligated to increase biliary pressure by obstruction (cholestasis),
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which leads to mild inflammation, cytokine production, and proliferation of biliary
epithelial cells (cholangiocytes), which generates reactive oxygen species (ROS) and
liver damage (Georgiev et al., 2008). In this model, collagen production results from the
activation of portal fibroblasts as well as HSCs. The BDL model is useful for studying
fibrosis reversibility because the biliary obstruction can be relieved by biliodigestive
anastomosis (Abdel-Aziz et al., 1990).
Chronic Administration of TCDD
In 2014, Pierre et al. reported that chronic exposure to TCDD elicited liver
fibrosis (Pierre et al., 2014). In this study, mice were treated with 25 µg/kg of TCDD for
2 days, 4 days, or once weekly for 42 days. Histological and biochemical examination of
liver tissue confirmed that TCDD stimulated the onset of fibrosis in wildtype mice, but
not in AhR-KO mice. Shortly thereafter, another lab reported that treatment of mice with
TCDD for 92 days produced periportal inflammation and fibrosis (Nault et al., 2016). It
was further demonstrated that chronic injury from TCDD treatment dysregulated
glycogen, ascorbic acid, and amino acid metabolism, which support ECM remodeling
and the progression to hepatic fibrosis (Nault et al., 2016). Studies described in this
dissertation utilized this 92-day chronic administration of TCDD to elicit liver fibrosis
and elucidate how cell-specific AhR signaling impacts HSC activation and the
development of liver fibrosis.
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Research Goal
The goal of this dissertation research was to determine how AhR signaling in
hepatocytes and HSCs impacts HSC activation and the development of liver fibrosis. It is
possible that TCDD directly activates HSCs through AhR signaling in these cells. There
are several lines of evidence to support the notion that HSCs are directly cellular targets
for TCDD. For example, studies from our lab previously reported that TCDD treatment
increased necroinflammation and HSC activation in mice treated with CCl4 (Lamb et al.
2016a). Furthermore, it was recently reported that treatment of mice with TCDD induced
HSC activation and liver fibrosis by activating AkT and NF-kB signaling pathways (Han
et al., 2017). Also, in vitro studies from our lab demonstrated that TCDD treatment
increased expression of α-smooth muscle actin (αSMA) expression, which is an HSC
activation marker, in the human HSC line, LX-2 (Harvey et al., 2016) (Figure 1.8).
Furthermore, exposure of rodents to TCDD was found to decrease vitamin A storage,
which is a well-established indicator of HSC activation (Hakansson and Hanberg, 1989).
These data support the notion that TCDD could directly activate HSCs in the mouse liver,
leading to the development of liver fibrosis.
However, we cannot rule out the possibility that TCDD induces HSC activation
indirectly, as a secondary response to hepatocyte injury and inflammation. Studies in
mice indicated that chronic TCDD exposure elicits liver fibrosis, and fibrosis is known to
be a wound-healing response directly stimulated by injury and inflammation, which drive
HSC activation and subsequent collagen deposition (Pierre et al., 2014; Lamb et al.,
2016a; Nault et al., 2016). Moreover, most of the studies of TCDD hepatotoxicity have
focused on the consequences of AhR activation in hepatocytes. In fact, studies using
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conditional AhR-KO mice demonstrated that AhR signaling in hepatocytes was required
for the gross hepatotoxic effects of TCDD (Walisser et al., 2005). The same study
reported decreased inflammation and necrosis in hepatocyte-specific knockout mice
(Walisser et al., 2005). Another recent study showed a decrease in fat accumulation in
liver tissues of hepatocyte-specific AhR KO mice (Tanos et al., 2012). Hence, it can be
concluded that AhR signaling in hepatocytes plays a crucial role in the development of
necrosis, steatosis, and inflammation in TCDD-treated mice.
Hepatocyte injury and inflammation go hand-in-hand. Injury drives inflammation,
and inflammation can elicit fibrogenesis by several mechanisms. For instance, apoptotic
hepatocytes induce inflammation by producing profibrogenic mediators (Seki and
Schwabe, 2015), which eventually induce liver fibrosis by releasing paracrine
stimulators, such as ROS and fibrogenic factors (Canbay, Friedman and Gores, 2004; Li
et al., 2008; Lee and Friedman, 2011). Other inflammatory cells, including lymphocytes
and neutrophils, can promote liver fibrosis by inducing lipid peroxidation (Casini et al.,
1997). Kupffer cells also have a leading role in liver fibrosis by producing ROS,
cytokines, and profibrogenic stimulators (Naito et al., 2004; Kolios, Valatas and
Kouroumalis, 2006). Collectively, these data establish a positive correlation between
inflammation and fibrosis.
In addition, there is increasing evidence to support a causal relationship between
hepatic steatosis/NASH and HSC activation, the latter of which drives collagen
deposition and liver fibrosis (Mann and Smart, 2002; Wobser et al., 2009; Karanjia et al.,
2016). One report suggests that NASH progresses to and fibrosis through a mechanism
that involves cytokine release from intrahepatic fat and ROS as a result of dysregulated
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lipid metabolism (Cusi, 2012). These findings support the idea that chronic exposure to
TCDD could elicit HSC activation indirectly as a result of TCDD-induced inflammation
and steatosis. Therefore, it is evident that TCDD may indirectly activate HSC by
inducing liver injury and inflammation through AhR signaling in hepatocytes (Figure
1.7). It is important to understand these secondary effects on HSC activation, because
they could also play an important role in exacerbating liver fibrosis.

Figure 1.7

Hepatic Stellate Cell activation

Quiescent HSCs function in storing vitamin A. Upon liver injury or direct activation of
HSCs, HSCs differentiate to a myofibroblast-like phenotype characterized by
proliferation, fibrogenesis, and loss of vitamin A storage. Hepatocyte toxicity may
increase the level of reactive oxygen species (ROS), activate Kupffer cells, and alter
cytokine production.
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Objectives and Hypothesis
We hypothesized that chronic TCDD treatment elicits liver fibrosis in vivo by
directly activating HSCs. An alternate hypothesis was that TCDD treatment activated
HSCs secondary to increasing liver damage, inflammation, and/or steatosis. Finally, it
was possible that TCDD increased HSC activation through a combination of effects on
both hepatocytes and HSCs.
In addition to understanding the cell-specific role of AhR signaling during
fibrosis, we also sought to understand the discrepancy between endogenous and
exogenous AhR activation as it relates to fibrosis development. It was recently reported
that treatment with the endogenous nontoxic AhR agonist, ITE, reduced HSC activation
and diminished liver fibrosis (Yan et al., 2019). Thereby it can be speculated that
endogenous and exogenous AhR activations have different outcomes. Interestingly,
understanding how AhR signaling modulates HSC activation in vivo is confounded by
concomitant hepatocyte damage and inflammation, both of which promote HSC
activation. These findings raise the intriguing possibility that HSC activation could be
therapeutically targeted by novel AhR ligands to diminish liver fibrosis, which is one of
the long-term goals of this research.
Studies in Chapter 2 focused on understanding how AhR signaling in HSCs and
hepatocytes contributes to HSC activation during TCDD-induced liver fibrosis. Cre-Lox
recombination was used to create mice with AhR-deficient hepatocytes or AhR-deficient
HSCs. To induce liver fibrosis, female, adult mice were gavaged with TCDD every four
days for 92 days, and HSC activation, liver damage, and inflammation were measured.
Understanding the cell-specific role of AhR signaling in fibrosis is important to the
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development of therapeutic AhR ligands to target and diminish HSC activation and
alleviate fibrosis.
The goal of the studies in Chapter 3 was to determine the direct effects of AhR
signaling on HSC gene expression in the absence of hepatocyte damage and
inflammation. To accomplish this, the AhR was knocked out of the human HSC line, LX2. Wild-type and AhR-KO cells were treated with TCDD (an exogenous AhR ligand) or
ITE (an endogenous AhR ligand) for 6 days of culture, and endpoints of HSC activation,
were measured. Results from these studies will be important for understating how AhR
signaling directly impacts HSC gene expression. They also shed light on understanding
how endogenous AhR signaling contributes to the repression of HSC activation and
fibrogenesis. Results from these studies are summarized, and future studies are discussed,
in the final chapter of this dissertation.
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CHAPTER TWO: CHRONIC TCDD TREATMENT INCREASES LIVER
MYOFIBROBLAST ACTIVATION THROUGH AHR SIGNALING IN
HEPATOCYTES
Abstract
Liver fibrosis is a pathological condition characterized by the excessive
deposition of collagen by activated hepatic stellate cells (HSCs). We previously reported
that exposure to the high-affinity aryl hydrocarbon receptor (AhR) ligand 2,3,7,8tetrachlorodibenzo-p-dioxin (TCDD) increases HSC activation in vitro, raising the
possibility that TCDD directly targets HSCs. However, few studies have specifically
examined AhR signaling during HSC activation. Furthermore, the development of liver
fibrosis in vivo depends on complex interactions between multiple types of cells,
including parenchymal hepatocytes, infiltrating immune cells, as well as HSCs. Recent
reports indicate that chronic exposure of mice to TCDD elicits liver fibrosis with
concomitant changes observed in hepatocyte metabolism, inflammatory cytokine
production, HSC activation, and ECM deposition. The goal of this project was to use
mice with AhR-deficient hepatocytes (AhRΔHep) or AhR-deficient HSCs (AhRΔHSC) to
determine how AhR activity in these cell populations impacts liver injury, inflammation,
HSC activation, and collagen deposition during TCDD-induced liver fibrosis. Control are
referred as AhRfl/fl mice. To induce liver fibrosis, mice were gavaged with TCDD (100
µg/kg) or peanut oil (vehicle) every four days for 92 days. Based on serum levels of
alanine aminotransferase, this dose of TCDD produced minimal hepatocyte necrosis that
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was consistent across all backgrounds. Exposure to TCDD induced marked hepatic
steatosis in AhRfl/fl mice and AhRΔHSC mice, but not in AhRΔHep mice, indicating that
hepatocyte AhR signaling mediated TCDD-induced steatosis. TCDD treatment increased
inflammatory cell infiltration in the liver of all mouse genotypes. In AhRfl/fl mice, TCDD
increased expression of the HSC activation markers Col1a1, Timp1, and Col3a1. TCDD
produced a similar effect in AhRΔHSC mice but failed to elicit HSC activation in AhRΔHep
mice. Increased collagen mRNA expression was not consistent with collagen protein
expression, with all mouse genotypes possessing low hepatic collagen protein, indicating
the possibility of TCDD-induced ECM turnover through a mechanism that does not
depend on AhR signaling in hepatocytes or HSCs. We conclude that chronic TCDD
exposure increases HSC activation indirectly through a mechanism that requires AhR
signaling in hepatocytes. It is possible that hepatic steatosis contributes to HSC activation
in TCDD-treated mice, whereas hepatocyte necrosis and hepatic inflammation do not
appear to play a major role.
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Introduction
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that
belongs to the basic helix-loop-helix Per/ARNT/Sim family of proteins (Hankinson,
1995). The AhR is well studied for mediating the toxicity of numerous environmental
contaminants, including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (FernandezSalguero et al., 1996). Upon ligand binding, the cytoplasmic AhR translocates to the
nucleus, where it heterodimerizes with the AhR nuclear translocator (ARNT) and binds
to conserved DNA sequences, which include a classical xenobiotic response element
(XRE), as well as a recently identified non-consensus XRE, to modulate the expression
of target genes (Huang and Elferink, 2012).
It is well established that TCDD toxicity is AhR-dependent, yet, at the organism
level, mechanisms of toxicity are poorly understood (Fernandez-Salguero et al., 1996).
For example, transcriptome-wide studies revealed that exposure to TCDD upregulates the
expression of numerous genes that do not contain XREs (Huang and Elferink, 2012). At
the molecular level, increased gene transcription of non-XRE-containing genes could
potentially be explained by TCDD/AhR-mediated epigenetic modifications and/or the
recruitment of alternative cofactors to the AhR/ARNT complex (Patrizi and de Cumis,
2018). However, at the tissue or organ level, it is likely that increased expression of nonXRE-containing genes at least partially reflects a compensatory response of various cell
populations to TCDD-induced tissue injury or dysfunction. Because the AhR is widely
expressed across all cell types, it has been difficult to distinguish between the direct
cellular effects of TCDD and the indirect effects that occur due to compensatory cellular
responses within the same tissue.
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Liver fibrosis is a pathological condition in which chronic injury and/or
unresolved inflammation drive the excessive deposition of extracellular matrix (ECM)
proteins by hepatic stellate cells (HSCs) (reviewed in Wynn, 2008). In the healthy liver,
HSCs are quiescent and function in the storage of vitamin A. However, upon liver injury,
these cells become activated and assume a myofibroblast-like phenotype characterized by
retinoid loss, increased proliferation, contractility, and fibrogenesis. In 2014, Pierre et al.
reported that chronic exposure of mice to TCDD produced liver fibrosis (Pierre,
Chevallier, Teixeira-clerc, et al., 2014). Exposure to TCDD for two weeks increased
expression of genes encoding HSC activation markers and inflammatory cytokines.
Histological features of fibrosis were observed after six weeks of TCDD treatment.
These effects were AhR-dependent, as they were not observed in AhR knockout mice
treated with TCDD. In mice, a single bolus of TCDD has been shown to produce hepatic
steatosis and immune cell infiltration (Boverhof et al., 2005). It has been proposed that
repeated TCDD treatment promotes the progression of steatosis to steatohepatitis with
fibrosis, resulting in a condition similar to non-alcoholic fatty liver disease (NAFLD)
seen in humans (Pierre, Chevallier, Teixeira-clerc, et al., 2014; Fader et al., 2015). In
support of this, Fader et al. demonstrated that treatment of mice with TCDD every 4 days
for 28 days dose-dependently altered expression of genes associated with hepatic lipid
metabolism, increased the accumulation of fat droplets within the liver, and increased the
number of F4/80+ cells (macrophages) in the liver (Fader et al., 2015). Nault et al.
extended this study to show that treatment of mice with TCDD for 92 days not only
increased hepatic fat accumulation and inflammation, but also produced hepatic collagen
deposition and differential expression of matrisome genes consistent with HSC activation
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(Nault et al., 2016). Furthermore, fibrosis development correlated with the reorganization
of metabolic activities in hepatocytes, including the redirection of glycogen, ascorbic
acid, and proline metabolism to support ECM remodeling.
The development of liver fibrosis is a complex phenomenon that involves many
pathways and cell types. Initial damage to hepatocytes and/or cholangiocytes initiates the
infiltration of immune cells to the liver. Persistent inflammation triggers profibrotic
signaling that further increases inflammation and elicits HSC activation, resulting in the
deposition of ECM proteins, including collagen. It is well known that the liver is a target
organ for TCDD toxicity, with endpoints that include hepatomegaly, moderate elevation
in serum alanine aminotransferase (ALT) levels, and modest periportal inflammation.
Studies using mice with hepatocyte-specific deletion of the AhR demonstrate that each of
these endpoints of TCDD toxicity requires a functional AhR in hepatocytes (Walisser et
al., 2005). Although parenchymal hepatocytes comprise ~80% of the cells in the liver,
the AhR is expressed in all liver cell populations, including the remaining nonparenchymal cells, which are comprised of HSCs, sinusoidal endothelial cells,
cholangiocytes, and resident macrophages (Kupffer cells). In mice with the hepatocytespecific AhR knockout, TCDD treatment still induced the expression of the classic AhRregulated genes, Cyp1a1 and Cyp1b1, and this was attributed to AhR signaling in nonparenchymal cell populations (Walisser et al., 2005). However, less is known regarding
the effects of TCDD on these cell populations.
It is possible that HSCs are direct cellular targets for TCDD during the
development of liver fibrosis. It has been reported that HSC express a functional AhR
and that the half-life of TCDD in HSCs is 52 days (compared to 13 days in hepatocytes)
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(Håkansson and Hanberg, 1989). However, studies with isolated rat HSCs found that a
single dose of TCDD had no effect on expression of the HSC activation marker, alphasmooth muscle actin (αSMA) (Hanberg, Kling and Hakansson, 1996). In contrast, we
previously found TCDD treatment increased proliferation and αSMA expression in a
human HSC line, LX-2 (Harvey et al., 2016). Interestingly, under typical cell culture
conditions, LX-2 cells exist in a quasi-activated state. It is possible that a single dose of
TCDD is not sufficient for increasing the activation of freshly isolated, quiescent HSCs
(Hanberg, Kling and Hakansson, 1996), but that it was sufficient for increasing endpoints
of activation in cells that were at least partially activated (Harvey et al., 2016). Thus, it is
possible that TCDD treatment could directly activate HSCs.
It is also possible that TCDD could activate HSCs and subsequently elicit fibrosis
by enhancing injury and inflammation. In fact, liver damage, inflammation, steatosis, and
increased mechanotension by cross-linking of ECM proteins are considered triggers for
HSC activation. One report suggests that the engulfment of hepatocyte apoptotic bodies
by HSCs can promote HSC activation (Canbay et al., 2003). This can occur when the
apoptotic bodies are engulfed by Kupffer cells, which induces the release of
profibrogenic mediators and pro-inflammatory cytokines (Canbay et al., 2003b).
Inflammatory cells drive HSC activation through the release of reactive oxygen species
(ROS) and profibrogenic mediators (Canbay, Friedman and Gores, 2004; Li et al., 2008;
Lee and Friedman, 2011). Inflammatory cells, such as lymphocytes and neutrophils, can
also activate HSCs by inducing lipid peroxidation (Casini et al., 1997). Thus, Kupffer
cells play a large role in HSC activation by inducing ROS production, cytokine release,
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and profibrogenic stimulation (Naito et al., 2004; Kolios, Valatas and Kouroumalis,
2006).
The goal of this study was to investigate the cell-specific role of AhR activation
during the development of liver fibrosis. We used Cre-Lox technology to generate mice
with a hepatocyte-specific or HSC-specific AhR knockout to determine the respective
contributions of hepatocyte damage, steatosis, inflammation on HSC activation and the
development of liver fibrosis.
Materials and Methods
Generation of Mice with AhR-Deficient Hepatocytes or AhR-Deficient HSCs
Mice expressing the floxed AhR gene (Ahrtm3.1Bra/J, The Jackson Laboratory, Bar
Harbor, ME), referred to as AhRfl/fl, were crossbred to produce male AhRfl/fl mice. For
hepatocyte-specific AhR knockout mice, referred to as AhRΔHep mice, female mice that
expressed the Cre recombinase transgene under the albumin reporter (Alb-Cre mice)
(B6N.Cg-Speer6-ps1Tg(Alb-Cre)21Mgn/J, The Jackson Laboratory) were bred to male AhRfl/fl
mice to produce AhRfl;Alb-Cre offspring. AhRfl;Alb-Cre female mice were then bred to AhRfl/fl
male mice to generate mice that were AhRfl/fl and hemizygous for Alb-Cre. AhRfl/fl mice
and wild-type Alb-Cre were used as controls.
Similarly, to generate mice with an HSC-specific AhR knockout, referred to as
AhRΔHSC mice, we used female mice that expressed Cre recombinase under control of the
human glial fibrillary acidic protein (GFAP) promoter (referred to as GFAP-Cre) (FVBTg(GFAP-cre)25Mes/J, The Jackson Laboratory). These mice were crossbred with male
AhRfl/fl mice to produce AhRfl; GFAP-Cre offspring. AhRfl; GFAP-Cre female mice were then
bred with AhRfl/fl male mice to generate AhRfl/fl mice that were heterozygous for GFAP-
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Cre. Several reports suggest that GFAP-Cre specifically target HSCs (Kocabayoglu et al.,
2016; Ceni et al., 2017; Alsamman et al., 2018).
Animal Treatment
TCDD (98% pure; Cambridge Isotope Laboratories, Andover, MA) was dissolved
in anisole and diluted in peanut oil to create a working stock of 10 µg/mL. Mice were
gavaged with either 100 µg/kg TCDD diluted in peanut oil or with peanut oil alone
(referred to as “Vehicle”) every 4 days for 92 days. At the end of the study, mice were
euthanized, and sera and liver tissue were collected (Figure 2.1). Liver was either flashfrozen in liquid nitrogen or fixed in UltraLight Zinc Formalin Fixative (PSL Equipment,
Vista, CA). Flash-frozen tissue and sera were stored at -80°C until assayed. For each
treatment group, 8-11 mice were used. Mice were housed in microisolator cages with a
12:12 hour light/dark cycle. Food and water were available ad libitum. Bodyweight was
monitored and recorded every 4 days, and liver weight was measured immediately after
euthanasia. All protocols and experiments were approved by the Institutional Animal
Care and Use Committee at Boise State University.
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Figure 2.1

Mouse Treatment Schedule

Female mice were used at 8-9 weeks of age. Mice were on one of three different genetic
backgrounds: AhRfl/fl (control); AhRΔHep (hepatocyte-specific AhR knockout); AhRΔHSC
(HSC-specific AhR knockout). Mice were gavaged with 100 µg/kg TCDD (gray) or
vehicle (white) every four days for 92 days and then euthanized. Eight to 11 mice were
used in each treatment group.

Serum Alanine Aminotransferase (ALT) Assay
Alanine aminotransferase (ALT) is a hepatocyte-specific enzyme that is released
into the blood upon injury. To measure serum ALT levels, we used an InfinityTM ALT
(GPT) (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer’s
protocol. Sera was diluted 1:5 in PBS, and samples were run in duplicates.
Inflammatory Cell Infiltration Staining
Liver sections (5-µm thick) were stained with hematoxylin and eosin (H&E) to
measure inflammatory cell infiltration as described elsewhere (Junqueira, Bignolas and
Brentani, 1979). Stained tissues were imaged using a compound microscope (Olympus
BX53). For densitometry, the pixel content of the outlined regions in five fields per
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mouse was quantified using ImageJ software (US National Institutes of Health) and
expressed as a percentage of total pixels.
Collagen Staining
Liver sections were stained with Sirius Red to visualize collagen as described
elsewhere (Junqueira, Bignolas and Brentani, 1979). The slides were imaged using a
compound microscope (Olympus BX53). For densitometry, the pixel content of the red in
five separate fields per mouse was quantified using ImageJ software and expressed as a
percentage of total pixels.
Lipid Staining
Frozen liver tissues were embedded in optimal cutting temperature (OCT)
reagent, and 10-µm sections were cut using a Cryostat Leica CM1950. Sections were
mounted on glass slides. Slides were incubated in 100% propylene glycol for 2 min and
stained with 0.7% Oil Red O (Alfa Aesar, Tewksbury, MA) solution dissolved in 100%
propylene glycol for 15 min. The slides were then rinsed with distilled water and
incubated with 85% propylene glycol for 1 min. Excess Oil Red O/ propylene glycol was
removed by rinsing with distilled water. Tissues were then counterstained with Mayer's
hematoxylin Gill No. 3 (Sigma-Aldrich, St. Louis, MO) for 1 min. Slides were imaged
using a compound microscope (Olympus BX53). The pixel content of the red regions in
five separate fields per mouse was counted using Image software and expressed as a
percentage of total pixels.
Measurement of mRNA Expression by Quantitative Real-Time PCR (qRT-PCR)
mRNA was extracted from 10 mg of frozen liver tissue using the E.Z.N.A.®
Total RNA Kit (Omega Bio-Tek, Norcross, GA). RNA purity was assessed using a
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Nanodrop (Thermo Fisher Scientific, Waltham, MA). mRNA was reverse transcribed
using a commercially available High-Capacity cDNA Reverse Transcription Kit (Thermo
Fisher Scientific, Waltham, MA). cDNA was then amplified using gene-specific primers
(Table 3.1) and Roche FastStart essential DNA green master reaction mix. Amplification
was performed using a LightCycler® 96 Thermocycler (Roche, Indianapolis, IN).
Samples were run in duplicate, and 8-11 samples were used in each treatment group.
Gene expression was normalized to GAPDH, and the relative expression was estimated
using the ΔΔCq method (Livak and Schmittgen, 2001). mRNA levels are expressed as
fold-change (mean ± SEM) relative to vehicle-treated AhRfl/fl mice.

Table 2.1
Gene
Acta2
Ccl2
Col1a1
Col3a1
Cyp1a1
Fgf21
Gapdh
Mmp13
Timp1
Tgfb1

Primer Sequences
Primer Sequence (5’to 3’)
TCC TCC CTG GAG AAG
TAT AGG TGG TTT CGT
ACT GAA GCC AGC TCT
TTC CTT CTT GGG GTC
GTC CCT GAA GTC AGC
TGG GAC AGT CCA GTT
CCT GGT GGA AAG GGT
CGT GTT CCG GGT ATA
GCC TTC ATT CTG GAG
CAA TGG TCT CTC CGA
CCG CAG TCC AGA AAG
CTG CAG GCC TCA GGA
CAA TGA CCC CTT CAT
GAT CTC GCT CCT GGA
GCC CTG GGA AGG AGA
GGA TTC CCG CAA GAG
CAC GGG CCG CCT AAG
GGT CAT CGG GCC CCA
TGC TAA TGG TGG ACC
CAC TGC TTC CCG AAT

Temp. (℃)
AGC
GGA
CTC
AGC
TGC
CTT
GAA
CCA
ACC
TGC
TCT
TCA
TGA
AGA
GAC
TCG
GAA
AGG
GCA
GTC

TAC
TGC
TTC
ACA
ATA
CAT
AT
TTA
TTC

60
CTC
GAC

60
60

G
C

CC
AA
CC
TG
TCC AGG
CAG G
CG
GA
A
TGA

62
60
62
60
60
67
55

RNA-Sequencing and Data Analysis
mRNA extraction, library preparation, and sequencing were performed at the
Novogene Corporation Inc. (Sacramento, CA). In brief, mRNA was isolated from 10 mg
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of liver tissue using poly-T oligo-attached magnetic beads. RNA quality was determined
using the Nano 6000 assay kit of the Bioanalyzer 2100 system (Agilent Technologies,
CA, USA), and samples with an RNA integrity number (RIN) > 6.8 were used for library
preparation. Transcriptome libraries were prepared using NEBNext® Ultra™ RNA
Library Prep Kit for Illumina (Biolabs, Ipswich, MA), and quality was determined by
Qubit2.0 and Agilent 2100. Finally, these libraries were sequenced on an Illumina Nova
6000 platform, and 150-bp paired-end reads were generated with a read depth of ~20M
per sample. Raw data were analyzed for the Per base sequence quality (>30), Per
sequence GC content, adapter (universal Illumina adapter), and adapter removal using
FASTQC v0.11.9. Reads were mapped to the mouse reference genome (GRCm38 release
96) using HISAT2 v2.1.0 (Kim, Langmead and Salzberg, 2015). Aligned reads were
counted using HTSeq v0.11.3 (Anders, Pyl and Huber, 2015). The obtained counts were
analyzed for differential expression using the Median-Ratio-Normalization method
(Maza et al., 2013) with Deseq2 v1.22.2 (Love, Huber and Anders, 2014). Fold-change
was calculated relative to counts in vehicle-treated AhRfl/fl mice. Gene expression was
considered differentially expressed if the adjusted p-value was < 0.05. The enrichment
analysis of the differentially expressed genes (DEGs) was performed in Cytoscape v3.7.0
using the ClueGov2.5.1 visualization tool.

Statistical Analysis
Statistical significance was determined based on a two-way ANOVA with
Bonferroni testing (p<0.05) using GraphPad Prism 8.01 software (GraphPad Software, La
Jolla, CA). Unless otherwise noted, data represent mean ± SEM. Means that do not share
a letter are significantly different from each other.
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Results
AhR Activity in AhRΔHep Mice and AhRΔHSC Mice
To confirm the cell-specific knockout of AhR, we measured the hepatic mRNA
expression of Cyp1a1, which encodes cytochrome P450 1A1, and Cyp1b1, which
encodes cytochrome P450 1B1. Cyp1a1 and Cyp1b1 are AhR-regulated genes, and the
expression of these genes is an accepted hallmark of AhR activation. In AhRfl/fl and
AhRΔHSC mice, TCDD treatment significantly increased Cyp1a1 mRNA expression
(Figure 2.2 A). However, in AhRΔHep mice, the TCDD-mediated induction of Cyp1a1
was not statistically significant. Similarly, TCDD treatment significantly increased
Cyp1b1 mRNA expression in AhRfl/fl and AhRΔHSC mice but not in AhR∆Hep mice (Figure
2.2 B). Given that hepatocytes make up ~90% of the cells in the liver, it is not surprising
that expression of Cyp1a1 and Cyp1b1 was markedly reduced in mice with the
hepatocyte-specific AhR knockout. In the AhR∆Hep mice, the small TCDD-induced
increase in Cyp1a1 and Cyp1b1 presumably reflects the contribution from nonparenchymal cells of the liver (Walisser et al., 2005).
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Figure 2.2

Assessing AhR Activity in AhRΔHep Mice and AhRΔHSC Mice

Hepatic mRNA levels of Cyp1a1 (A), and Cyp1a1 (B) are expressed as fold-change
(mean ± SEM) relative to vehicle-treated AhRfl/fl mice (p < 0.05). Means that do not
share a letter are significantly different from each other (p < 0.05).

Hepatotoxic Effects of Mice Treated with TCDD
In order to evaluate the impact of TCDD-induced hepatotoxicity on HSC
activation in our model system, we investigated gross markers of hepatotoxicity. In
response to TCDD, all mice showed marked hepatomegaly, which was determined by the
increase in the liver-to-body weight ratios (Figure 2.3A). Serum activity levels of alanine
aminotransferase (ALT) were measured as a marker of hepatocellular necrosis. ALT is a
liver-specific enzyme that catalyzes the synthesis of alanine from glutamate, released into
the blood following liver injury, namely hepatocyte lysis. Chronic TCDD treatment
produced minimal liver damage, regardless of AhR knockout (Figure 2.3B).
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Figure 2.3

Hepatotoxic Effects of TCDD-Treated Mice

(A) Liver weight to body weight ratios after 92 days of treatment. (B) Data represent
mean (± SEM) serum ALT levels. Means that do not share a letter are significantly
different from each other (p < 0.05).

TCDD-Induced Inflammatory Cell Infiltration Occurs Independently of AhR Signaling in
Hepatocytes and HSCs.
To identify the inflammatory cell infiltration, the liver tissues were stained with
H&E. TCDD treatment increased inflammatory cell infiltration around the portal regions,
regardless of AhR knockout (Figure 2.4A, B). We also quantified the mRNA levels of
inflammation marker Ccl2, which encodes monocyte chemoattractant protein-1 (MCP-1).
The TCDD-treated Ccl2 mRNA expression in AhRfl/fl and AhRΔHep mice reveals a
relative increase compared to AhRΔHep mice, when compared to vehicle-treated mice
(Figure 2.4C).
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Figure 2.4

TCDD Treatment Induces Inflammation in the Livers of Both
AhRΔHep and AhRfl/fl Mice.

(A) H&E-stained liver tissue from vehicle- and TCDD-treated mice (100X magnification;
scale bar = 500 µm). (B) Pixel content of the inflammatory regions was quantified in five
fields per mouse and expressed as a percentage of total pixels. (C) Hepatic mRNA levels
of Ccl2 are expressed as fold-change (mean ± SEM) relative to vehicle-treated AhRfl/fl
mice. Means that do not share a letter are significantly different from each other (p <
0.05).
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TCDD Treatment Does Not Induce Lipid Deposition in the Livers of AhRΔHep Mice.
It is well established that AhR activation causes spontaneous fatty liver
(Fernandez-Salguero et al., 1996). However, the cell-specific role of AhR remains largely
unknown. To determine the cell-specific contribution of AhR signaling in mediating
hepatic steatosis, which in turn can affect HSC activation, we measured the lipid
deposition in the liver. TCDD treatment induced both macrosteatosis and microsteatosis
in AhRfl/fl mice and AhRΔHSC. In contrast, livers from the AhRΔHep mice did not show any
marked lipid accumulation upon TCDD treatment (Figure 2.5A). Quantification of lipid
staining revealed a significant increase in Oil Red O-positive pixels in AhRfl/fl mice and
AhRΔHSC mice, when compared to vehicle-treated mice. However, oil Red O staining was
minimal in AhRΔHep mice (Figure 2.5B). mRNA levels of Fgf21, which is a hepatokine
that reflects liver fat accumulation (Rusli et al., 2016), were significantly increased in
TCDD-treated AhRfl/fl and AhRΔHSC mice but not in AhRΔHep mice (Figure 2.5C). This
supports the Oil Red O staining. Furthermore, to determine the cell-specific role of AhR
in lipid metabolism, makers of lipid accumulation, fatty acid synthesis, and β-oxidation
were assessed using RNA-seq (Figure 2.6). Results indicate that expression of the CD36
(Cd36) gene, which encodes a membrane protein capable of taking up circulating fatty
acids (Abumrad et al., 1993), was induced significantly following TCDD treatment in
AhRfl/fl and AhRΔHSC mice but not in AhRΔHep mice. Expression of fatty acid synthase
(Fasn) and long-chain fatty acid ligase (Acsl1), both of which encode proteins crucial for
fatty acid synthesis, were repressed in AhRfl/fl and AhRΔHSC mice treated with TCDD.
Most genes pertaining to β-oxidation demonstrated at least a marginal repression in
AhRfl/fl and AhRΔHSC mice, but not in AhRΔHep mice following TCDD treatment.
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Figure 2.5

TCDD Treatment Does Not Induce Lipid Deposition in the Livers of
AhRΔHep mice.

A) Oil Red O stained liver tissue from TCDD-treated mice (200X magnification; scale
bar = 200 µm). (B) The pixel content of the red regions was quantified in five fields per
mouse and expressed as a percentage of total pixels. (C) Hepatic mRNA levels of Fgf21
are expressed as fold-change (mean ± SEM) relative to vehicle-treated AhRfl/fl mice (n=811). Means that do not share a letter are significantly different from each other (p < 0.05).
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Figure 2.6

TCDD Treatment Modulated Genes Associated With Lipid
Metabolism in AhRΔHep mice.

RNA-seq was used to assess the expression of lipid accumulation, fatty acid synthesis,
and beta-oxidation genes. Gene expression for all treatment groups was normalized to
vehicle-treated AhRfl/fl mice. Blue tiles indicate repression, and red tiles indicate
induction of gene expressions. Relative transcript abundance depicts the mean of the
normalized transcript counts of all samples in each individual genes, normalizing for
sequencing depth. Green tiles indicate a high (>1000) relative transcript abundance and
white tiles indicate a low (<10) relative transcript abundance. The letters V and T
represents Vehicle and TCDD treatments, respectively.
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TCDD Treatment Increases HSC Activation Markers in the Livers of AhRfl/fl and
AhRΔHSC Mice, But Not in AhRΔHep Mice.
To determine how AhR ablation impacted HSC activation following chronic
TCDD treatment, the expression of several HSC activation markers was investigated. The
mRNA and protein levels of HSC activation marker, α-smooth muscle actin (αSMA) was
measured by RT-qPCR and immunofluorescence staining. TCDD treatment elicited
minimal changes in αSMA mRNA and protein levels (Supplementary Figure 2.1). Other
markers of HSC activation, namely collagen type I (Col1a1), collagen type III (Col3a1),
and tissue inhibitor of metalloproteinases-1 (Timp1), were assessed by RT-qPCR.
Col1a1, Col3a1, and Timp1 mRNA expression were significantly increased in TCDDtreated AhRfl/fl mice and AhRΔHSC mice, compared to vehicle-treated mice. However, in
AhRΔHep mice, the TCDD-induced increase was minimal for all three genes (Figure 2.7A,
B, and C). HSC activation markers were also assessed using RNA-seq to determine the
cell-specific effects of AhR knockout. Genes such as Tgfb1, and Tgfb2 were unaffected
by AhR knockout (Figure 2.7D).
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Figure 2.7

TCDD Increases HSC Activation Markers in AhRfl/fl Mice But Not in
AhRΔHep Mice.

(A-C) Hepatic mRNA levels of HSC activation markers Col1a1, Timp-1, and Col3a1.
mRNA levels are expressed as fold-change (mean ± SEM) relative to vehicle-treated
AhRfl/fl mice (n=8-11). Means that do not share a letter are significantly different from
each other (p < 0.05). (D) RNA-seq was used to assess expression of HSC activation
associated genes. Gene expression for all treatment groups was normalized to vehicletreated AhRfl/fl mice. Blue tiles indicate repression, and red tiles indicate induction of
gene expressions. Relative transcript abundance depicts the mean of the normalized
transcript counts of all samples for each gene, normalizing for sequencing depth. Green
tiles indicate a high (>1000) relative transcript abundance, and white tiles indicate a low
(<10) relative transcript abundance. The letters V and T represent Vehicle and TCDD
treatment, respectively.
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TCDD Induced Collagen Expression and Modulated Extracellular Matrix Remodeling
Genes Regardless of AhR-Knockout.
To visualize hepatic collagen content, liver tissues were stained with Sirius Red.
This revealed that TCDD induced periportal fibrosis across all the groups regardless of
AhR knockout (Figure 2.8A). However, the Sirius Red quantification revealed that the
change across all the groups was minimal (Figure 2.8B). The minimal change may be
attributed to the degradation of collagen fibers by matrix metalloproteases (MMPs). To
investigate how TCDD impacts extracellular matrix remodeling genes in cell-specific
knockout mice, we measured the mRNA expression of several genes by RT-qPCR and
differential gene expression by RNA-sequencing. mRNA levels of Tgfβ1 and Mmp13
(which encodes matrix metallopeptidase 13) increased upon TCDD treatment regardless
of AhR knockout (Figure 2.9A, B). The TCDD-induced expression of lysyl oxidase (Lox)
mRNA was similar levels across all genotypes (Figure 2.9C).
The RNA-seq data revealed that Col1a1, Col3a1, Col6a1, Col6a2, and Col6a3
expression was induced in AhRfl/fl and AhRΔHSC mice upon TCDD treatment (Figure
2.9D). In contrast, the increase in AhR∆Hep mice was minimal or absent upon TCDD
treatment. TCDD also induced expression of Mmp2, Mmp9, Mmp13, and Mmp14 genes,
regardless of AhR knockout. TCDD increased mRNA expression of Serpine1 (which
encodes PAI-1), Plat (which encodes tissue plasminogen activator; tPA), and Plau
(which encodes plasminogen activator, urokinase; uPA) in AhRfl/fl and AhRΔHSC mice but
not in AhR∆Hep mice.
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Figure 2.8

Chronic TCDD Treatment Induced Collagen Expression in the Liver
Regardless of AhR-Knockout

(A) Sirius Red-stained liver tissue from vehicle- and TCDD-treated mice (100X
magnification; scale bar = 500 µm). (B) Densitometry of Sirius Red-staining in five
sections per mouse (8-11 mice per treatment group).
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Figure 2.9

TCDD Treatment Modulated Expression of Extracellular Matrix
Remodeling Genes Regardless of AhR-Knockout

(A-C) Hepatic mRNA levels of the pro-fibrogenic mediators Tgfβ1, Mmp13, and Lox are
expressed as fold-change (mean ± SEM) relative to vehicle-treated AhRfl/fl mice (n=811). Means that do not share a letter are significantly different from each other (p < 0.05).
(D) RNA-seq was used to assess the expression of ECM remodeling-related genes. Gene
expression for all treatment groups was normalized to vehicle-treated AhRfl/fl mice. Blue
tiles indicate repression of gene expression, and red tiles indicate the induction of gene
expression. Relative transcript abundance represents the mean of the normalized
transcript counts of all samples. Green tiles indicate a high (>1000) relative transcript
abundance, and white tiles indicate a low (<10) relative transcript abundance. The letters
V and T represent Vehicle and TCDD treatments, respectively.
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Discussion
The present study investigated the cell-specific role of AhR signaling in
hepatocytes and HSCs during liver injury, inflammation, and HSC activation incurred by
chronic exposure to TCDD. To address the cell-specific contributions, we used mice in
which the AhR was removed from either hepatocytes or from HSCs. A recent study has
demonstrated that TCDD treatment increases HSC activation in vitro (Harvey et al.,
2016). This led us to speculate that chronic exposure to TCDD may also directly activate
HSCs in the mouse liver.
No marked elevation in serum ALT levels was observed among treatment groups
(Figure 2.3B), possibly due to the clearance of ALT by Kupffer cells, as the last dose of
TCDD was given on day 88, and serum was collected on day 92 (Radi et al., 2011). This
was further supported by the fact that the half-life of ALT is 48 hours (Dufour et al.,
2000). This mild liver damage is consistent with previous reports in which mice were
exposed to chronic TCDD treatment (Fernandez-Salguero et al., 1996; Nault et al.,
2016). Overall, a more extensive liver damage would likely have been observed if mice
had been treated with a higher dose of TCDD due to the fact that the mice used in our
experiments contained the relatively insensitive 'd' allele of the AhR.
Our results indicate that chronic exposure to TCDD induced periportal fibrosis
and inflammation, which is consistent with a previous report (Nault et al., 2016).
However, we observed a relatively mild induction of fibrosis, based on minimal
distribution and intensity of Sirius red-stained fibers throughout the liver. It is possible
that the dose selected for these experiments failed to elicit robust tissue injury,
inflammation, and/or fibrogenesis. This was supported by the observation that no
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treatment-related deaths were observed (data not shown), unlike other studies that
reported having more than 50% of treatment-related deaths. Our findings indicate that
TCDD-induced collagen-synthesis is dependent on AhR signaling in hepatocytes.
Further, the repression of Col6a2 and Col6a3 mRNA expression in AhR∆Hep mice
supports the fact that AhR signaling in hepatocytes is an absolute requirement for
collagen gene expression.
We and others have previously shown that TCDD modulates expression of ECM
remodeling genes in the liver (Andreasen et al., 2006; Pierre et al., 2014; Lamb et al.,
2016). It is possible that chronic TCDD treatment enhances the turnover of collagen by
enhancing collagenase activity, thereby limiting the accumulation of collagen. Our results
indicate that the mRNA expression of matrix metalloproteinases, and genes in the
plasminogen activator/plasmin system, which in turn regulate MMP activation, did not
change much in cell-specific knockout mice. Interestingly, expression of the gene
encoding PAI-1 (Serpine1), which is a negative regulator of MMP activity, was severely
repressed in AhR∆Hep mice, but this did not correlate with reduced MMP expression.
In this study, ECM stiffness was not directly measured. Several studies have
demonstrated the role of ECM stiffness in HSC activation during the development of
liver fibrosis (Priya and Sudhakaran, 2008; Saneyasu, Akhtar and Sakai, 2016). The
predominant ECM protein in fibrosis is collagen. A recent study reported that LOX
depended on the mechanism of collagen cross-linking in liver fibrosis in carbon
tetrachloride-treated mice (Liu et al., 2016). Based on earlier studies, the mechanical
tension can be generated as a result of inflammation (Liu et al., 2016) or through a
TGFβ1-mediated pathway. Both promote the covalent cross-linking by LOX for
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stabilization of collagen (Van Der Slot et al., 2005). Our results indicate that TCDD
treatment produced a similar level of inflammatory cell infiltration and Lox and Tgfb1
mRNA expression regardless of AhR knockdown. Hence, it can be predicted that hepatic
stiffness would also be similar among genotypes.
Numerous HSC activation markers have been identified, some of which are
induced while others are repressed. The expression of some HSC activation markers
depends on the model system, and some of these activation markers could require
secondary signals obtained through injury and inflammation. For instance, in the present
study, although elevated Acta2 mRNA and protein levels are considered hallmarks of
HSC activation, TCDD did not elicit remarkable expression of this marker
(Supplementary Fig. S2). It is possible that the dose selected in this study was not
sufficient to induce a significant change in mRNA and protein expression. However,
other reported activation markers such as type I collagen (Col1a1), tissue inhibitor of
matrix metalloproteinase-1 (Timp1), and type III collagen (Col3a1) (Hemmann et al.,
2007; Mannaerts et al., 2013) reveal that AhR signaling in hepatocytes is important for
HSC activation during TCDD-induced liver fibrosis. Furthermore, RNA-seq did not
identify any changes in gene expression that would explain decreased HSC activation in
AhRΔHep mice.
Our findings corroborate previous reports that activation of AhR by TCDD
induces hepatic steatosis (Walisser et al., 2005; Lee et al., 2008; Xu et al., 2016). In
addition, our data suggest that AhR signaling in HSCs is not an absolute requirement for
steatosis. The lack of steatosis observed in AhRΔHep mice could indicate that steatosis
contributes to HSC activation in this model system. The relationship between steatosis
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and HSC activation is fairly well documented. For example, it has been reported that
HSC activation correlates with steatosis during human liver fibrosis (Reeves et al., 1996;
Feldstein et al., 2005). Another study reported that hepatic steatosis accelerates the
activation and proliferation of HSCs through the activation of the phosphatidylinositol 3kinase (PI-3-kinase) pathway (Wobser et al., 2009), which is known to contribute to HSC
proliferation and collagen secretion (Friedman, 2000). Furthermore, hepatic steatosis
induces the expression of the profibrogenic genes TGF-β, tissue inhibitor of metalloproteinase-1 (TIMP-1), TIMP-2, and matrix-metalloproteinase-2, as well as nuclearfactor kappaB-dependent expression of MCP-1 in HSCs, all leading to HSC activation
(Wobser et al., 2009). Increasing evidence suggests the association of hepatic steatosis
and lipid peroxidation (Macdonald et al., 2001) with mitochondrial abnormalities, which
induce overproduction of reactive oxygen species, can activate HSCs (Caldwell et al.,
1999). Furthermore, Cyp2e1 expression was increased in NAFLD (Aubert et al., 2011),
which can activate HSCs and increase type I collagen secretion (Nieto et al., 1999).
Finally, Fgf21, a hepatokine and a potential plasma marker for NAFLD (Rusli et al.,
2016). During liver injury, FGF21 is produced from hepatocytes and HSCs and has been
shown to directly induce HSC activation (Schumacher and Guo, 2016). It was reported
that AhR signaling in hepatocytes attenuates FGF21 expression (Girer et al., 2016). It is
possible that the TCDD-induced Fgf21 levels in our model system represent a secondary
effect of steatosis. Hence, it can be predicted that decreased HSC activation in AhRΔHep
mice treated with TCDD could result from decreased lipid accumulation.
TCDD-mediated differential expression of lipid metabolism suggests that TCDD
induces lipid accumulation and decreases β-oxidation in a hepatocyte-specific, AhR-
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dependent manner. Genes pertaining to lipid accumulation (Cd36, Dgat2), de novo
synthesis of fatty acids (Fasn, Acsl1), and β-oxidation of fatty acids (Fgf21, Pnpla3) were
among the most induced genes. CD36 is a glycoprotein that facilitates membrane
transport of fatty acids. It was previously shown that hepatocyte-specific disruption of
CD36 attenuates fatty liver in the high-fat diet-fed mice (Wilson et al., 2016). Our data
support this finding. Interestingly, a decrease in Dgat2 expression in AhRΔHep mice,
which largely determines hepatic de novo synthesis of triglycerides (Wurie, Buckett and
Zammit, 2012), suggests that TCDD induces fatty acid accumulation and prevents
triglyceride synthesis through a mechanism that relies on AhR signaling in hepatocytes. It
can be speculated that TCDD decreases de novo synthesis of fatty acids through Fasn and
Acsl, which are dependent on hepatocyte AhR signaling. Our data show that TCDD
decreases gene expression for phospholipase 3 (Pnpla3). The deletion of the Pnpla3
variant Pnpla3 I148M has been shown to increase hepatic steatosis (Wurie, Buckett and
Zammit, 2012). In summary, increased steatosis is dependent on hepatocyte-specific
AhR, which occurs mostly by elevation of Cd36 and repression of Pnpla3.
In conclusion, results from this study indicate that chronic TCDD exposure
indirectly increases HSC activation through a mechanism that requires AhR signaling in
hepatocytes. It is possible that hepatic steatosis contributes to HSC activation in TCDDtreated mice, whereas hepatocyte necrosis and hepatic inflammation do not appear to play
a major role, although the precise mechanism remains unclear. TCDD-induced synthesis
and degradation of collagen in fibrosis are independent of AhR signaling in hepatocytes
and HSCs. Collectively, results from this project imply that it may be more fruitful to
strategically target AhR signaling in hepatocytes, instead of in HSCs directly, when
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developing new therapeutic AhR ligands to modulate HSC activation and limit or reverse
liver fibrosis.
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Supplementary Data

Supplementary Figure 2.1 Protein and mRNA Levels of αSMA
(A) αSMA immunofluorescence stained liver tissue from vehicle- and TCDD-treated
mice (100X magnification and scale bar = 500 µm) across all the groups. The αSMA
expression was measured using fluorescence microscopy (anti-αSMA, red; DAPI, blue).
Scale bar = 100 μm. (B) The pixel content of the red regions was quantified in five fields
per mouse and expressed as a percentage of total pixels. (C) Hepatic mRNA levels of
FGF-21 are expressed as fold-change (mean ± SEM) relative to vehicle-treated AhRfl/fl
mice (n=8-11). Means that do not share a letter are significantly different from each other
(p < 0.05).

80

Supplementary Figure 2.2 Analysis of Gene Expression Variances Using Principal
Component Analysis (PCA).
(A) PCA analysis of gene expression across the treatments in both wild-type and AhRdeficient LX-2 cells. The components PC1 and PC2 define the x- and y-axis,
respectively. The distance between any two points represents the variance in gene
expression between them. (A) PCA plot was generated using the rlog transformation (rld)
function of normalized count data. (B) PCA plot was generated using the variance
stabilizing transformation (VST) function of normalized count data.
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Supplementary Figure 2.3 MA Plots of Differentially Expressed Genes
(A-E) MA plots for differentially expressed genes (red) enriched for the defined
comparisons shown on the bottom of each figure. The X- and Y-axis of the plots
indicates the "mean of normalized counts" and log2 fold-change, respectively.
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CHAPTER THREE: ROLE OF ARYL HYDROCARBON RECEPTOR SIGNALING
IN HEPATIC STELLATE CELL ACTIVATION USING LX-2 CELLS
Abstract
Accumulating evidence suggests a complex role for aryl hydrocarbon receptor
(AhR) signalig in liver fibrosis. Fibrosis is an abnormal wound healing response
characterized by excessive deposition of collagen by activated hepatic stellate cells
(HSCs). We recently reported that AhR signaling increases HSC activation in vitro and in
the liver of mice treated with chronic carbon tetrachloride. In contrast, another recent
study reported that AhR prevents the activation of HSC and liver fibrosis. To investigate
the mechanistic roles by which AhR signaling regulates HSC activation, we sought to
create a novel modified human HSC line, LX-2, that does not express a functional AhR.
To disrupt AhR gene expression, CRISPR/Cas9 technology was used, which allowed for
precise and targeted mutation of exons 2 within the AhR gene. The wildtype and AhRknocked out (AhR-KO) LX-2 cells were treated with a prototypical exogenous AhR
ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), or the non-toxic endogenous AhR
ligand 2-(1' H-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE) and
incubated for 6 days for culture-induced activation. RNA-sequencing data revealed 9720
differentially expressed genes (DEGs) in untreated AhR-KO LX-2 cells compared to
untreated wildtype LX-2 cells. AhR gene deletion was found to increase the protein and
mRNA expression of alpha-smooth muscle actin (αSMA) and mRNA expression of
several other HSC activation markers, such as collagen type III (COL3A) and insulin-like
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growth factor binding protein 3 (IGFBP3). AhR gene deletion from LX-2 cells decreased
cell proliferation and altered the expression of proliferation-related genes, including
CCND1 (cyclin1) and CDKN1A (p21). Extracellular matrix remodeling (ECM) genes
were also modulated in AhR-KO LX-2 cells, which indicates that endogenous AhR
activation may play a role in ECM remodeling. No significant differences were observed
in the activation of LX-2 cells treated with TCDD and ITE ligands. We conclude that
endogenous AhR activation prevents HSC activation and modulates the expression of
genes associated with proliferation and ECM remodeling.
Introduction
Liver fibrosis is a wound healing process characterized by the excessive
deposition of extracellular matrix (ECM) proteins by activated hepatic stellate cells
(HSCs) (Wynn, 2008). The role and importance of HSCs as primary collagen-producing
cells contributing to liver fibrosis is well established (Fernandez-Salguero et al., 1996;
Moreira, 2007; Iwaisako et al., 2014). Some important triggers for HSC activation are
cytokine and profibrogenic mediators produced during hepatocyte injury and
inflammation (Casini et al., 1997; Canbay et al., 2003; Kisseleva and Brenner, 2008).
Activated HSCs are characterized by increased proliferation, the production of cytokines
and profibrogenic mediators, and the synthesis of ECM proteins, such as collagen type I
(Tsukamoto, 1999; Kisseleva and Brenner, 2007). The cytokines and profibrogenic
mediators produced from HSCs can function in an autocrine stimulus (Tsukamoto, 1999).
Overall, HSC activation is a complex event interplayed by many cells and stimuli, and
understanding the molecular mechanism is essential for liver fibrosis therapeutics.
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Several studies have implicated a role for aryl hydrocarbon receptor (AhR) in
mediating HSC activation and liver fibrosis (Fernandez-Salguero et al., 1996; Harvey et
al., 2016; Nault et al., 2016). The AhR is a ubiquitously expressed, soluble receptor that
functions as a ligand-activated transcription in response to endogenous and exogenous
ligands (Nguyen and Bradfield, 2008). The AhR is important for mediating the toxicity
associated with exposure to environmental toxicants, such as 2,3,7,8-tetrachlorodibenzop-dioxin (TCDD) (Fernandez-Salguero et al., 1996). It was later discovered that AhR
activation by endogenous ligands contributes to the regulation of physiological processes
such as cell cycle regulation, inflammation, development, and immunity, although
mechanisms by which this occurs are incompletely understood (Nebert and Karp, 2009;
Puga, Ma and Marlowe, 2009; Thatcher et al., 2015). Understanding how endogenous
ligands impact AhR activation in HSCs is important for determining the likelihood that
AhR signaling could be therapeutically targeted to diminish liver fibrosis.
The role of AhR signaling in HSC activation is unclear. We previously reported
that sub-chronic exposure to TCDD results in increased necroinflammation and HSC
activation, while a single treatment of TCDD also increased expression of HSC activation
markers in vitro (Harvey et al., 2016; Lamb et al., 2016a). This was corroborated by a
recent study that showed that TCDD induced HSC activation via activating protein
kinase-B/Akt and NF-kB signaling pathways (Han et al., 2017). In contrast, treatment
with the non-toxic, endogenous AhR agonist, 2-(1'H-indol-3'-carbonyl) thiazole-4carboxylic acid methyl ester (ITE) has been reported to reduce HSC activation and
mitigate liver fibrosis (Yan et al., 2019). Furthermore, primary cells isolated from HSCspecific AhR knockout mice showed increased HSC activation (Yan et al., 2019). These
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inconsistencies suggest the possibility that the AhR elicits different signaling pathways
and transcription profiles in response to exogenous and endogenous ligands.
Understanding how AhR signaling modulates HSC activation in vivo is typically
confounded by concomitant hepatocyte damage and inflammation, both of which
promote HSC activation. Therefore, to understand the discrepancies of AhR signaling in
HSCs at the cellular and molecular level, it would be ideal to use a model system in
which hepatocyte damage and inflammation were absent.
The goal of this study was to determine how exogenous and endogenous AhR
signaling impacts HSC activation in the absence of hepatocyte damage and inflammation.
We used CRISPR/Cas9 technology to create a AhR-deficient variant of the human HSC
line, LX-2. LX-2 cells were originally isolated from a healthy human liver and
immortalized by transfection with SV40 T-antigen (Xu et al., 2005). These cells display a
quasi-activated phenotype and express a functional AhR (Harvey et al., 2016). Gene
expression in LX-2 cells is remarkably similar to human HSCs (Xu et al., 2005). These
characteristics of LX-2 cells make it an ideal in vitro model to study AhR signaling in
HSCs. We hypothesized that AhR activation with the endogenous agonist ITE would
repress activation in wildtype LX-2 cells compared to untreated and TCDD-treated cells.
We further hypothesized that this repression would be absent in AhR-deficient LX-2 cells
and in wild-type LX-2 cells treated with an AhR antagonist (CH223191).
Materials and Methods
LX-2 Cell Culture
Human LX-2 cells (Merck, Kenilworth, NJ), were cultured in Dulbecco's
modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS;
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Biowest, Riverside, MO), 1 mM sodium pyruvate, and 100 U/mL penicillin/streptomycin
in a 5% CO2 humidified atmosphere incubator at 37 °C. Cell passage was performed on
70% confluent cells by trypsinization with 0.25% trypsin-EDTA (Sigma, St. Louis, MO).
Generation of AhR-Knockout LX-2 Cells Using CRISPR/Cas 9
A Gene Knockout Kit for human AHR was purchased from Synthego (Redwood
City, CA). The online Synthego design tool (https://design.synthego.com/#/) was used to
design three unique guide RNA (gRNA) sequences to target exon-2 of the human AHR
gene. All gRNAs from the kit were conjugated to the Synthego modified EZ scaffold. A
gRNA sequence that targeted the human RELA gene served as a positive control, as the
editing efficiency of this gRNA was previously established. gRNA sequences were
computationally analyzed for potential off-target effects using COSMID online software
(Cradick et al., 2014). Ribonucleoproteins (RNPs) were prepared according to the
manufacturer's specifications. In brief, 30 μM of gRNA was incubated with 20 pmol of
Cas9 nuclease (from Streptococcus pyogenes) containing two nuclear localization
sequences for 10 minutes at room temperature in 1X Tris-EDTA (TE) buffer, pH 8.0.
LX-2 cells were transfected using the Cell Line Nucleofector Kit V, according to the
manufacturer's specifications (LONZA, Basel, Switzerland). Briefly, LX-2 cells were
trypsinized at 70% confluency, and 2 × 106 cells were resuspended in 93 μL of
Nucleofector Solution V and 7 μL of previously prepared individual RNPs.
Electroporation was performed using a Nucleofector™ II/2b Device (LONZA, Basel,
Switzerland) on program Y-01. After transfection, LX-2 cells were grown for 3 passages.
Then cells were trypsinized, 50,000-100,000 cells were lysed, and DNA was collected
using the GeneArt® Genomic Cleavage Detection Kit (Thermo Fisher Scientific,
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Waltham, MA). A region around exon 2 of the human AhR gene was amplified by PCR
using designed primers (Invitrogen, Carlsbad, CA) (Supplementary Table S1). Amplified
products were sequenced at the Molecular Research Core Facility at Idaho State
University (Pocatello, ID) using the Applied Biosystems 3130xl Genetic Analyzer.
Genome editing of exon 2 was analyzed using Inference of CRISPR Edits (ICE)
(Synthego, https://ice.synthego.com/#/), which compares sequencing results from treated
and untreated RNPs. Single-cell clones were isolated (Supplementary Materials and
Methods). DNA from individual clones was sequenced, and the purity and editing
efficiency (percentage of cells carrying mutations) was determined using ICE analysis.
Chemical Treatment of LX-2 Cells
TCDD was purchased from Cambridge Isotope Laboratories (Andover, MA); ITE
was purchased from Sigma (St. Louis, MO); CH233191 was purchased from Fisher
Scientific (Waltham, MA). Working stocks of 1 μM and 1 nM were prepared by diluting
each chemical in dimethyl sulfoxide (DMSO). LX-2 cells (2x104 cells) were plated in
tissue culture plates or on 22 x 22 mm glass coverslips. After reaching 30-70 %
confluency, cells were treated with 10 nM TCDD (Harvey et al., 2016), 1 μM ITE
(Yoshida et al., 2012), or 1 μM CH223191 (Walla et al., 2012; Yoshida et al., 2012) at
0.1% vol/vol. Controls consisted of cells treated with an equivalent volume of DMSO
alone (0.1% vol/vol) or cells that were left untreated altogether. One to six days after
treatment, cells were collected by trypsinization (0.25% trypsin-EDTA; Sigma, St. Louis,
MO) for analysis.
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Proliferation Assay
Viable LX-2 cells were counted using a hemocytometer based on trypan blue dye
exclusion. The trypsinized cells were diluted from 200 μL to 1200 μL with DMEM media
to obtain raw counts of 20 to 40 cells per image. For field counting, cells in DMEM were
diluted with trypan blue in a 1:1 ratio. Cells from two fields for each sample were
counted in a light microscope with 100X magnification. Each treatment had 3 samples.
The percentage of dead cells in each treatment was less than 1%.
Immunofluorescence Detection of αSMA
LX-2 cells (2x104 cells) were plated on 22 x 22 mm glass coverslips and treated
as described above. After 6 days of incubation, cells were fixed by incubating coverslips
in 2% paraformaldehyde for 15 minutes. Cells were then permeabilized by a 15-minute
incubation in phosphate buffered saline (PBS) containing 0.1% Triton X-100, and antigen
retrieval was achieved using PBS containing 0.5% SDS. Non-specific regions were
blocked with PBS containing 5% bovine serum albumin (BSA) for 45 minutes at room
temperature. Cells were incubated overnight at 4°C with mouse anti-αSMA monoclonal
antibody (MS-113-PO, Thermo Fisher Scientific, Waltham, MA) diluted 1:100 in PBS
containing 0.5 % BSA. Coverslips were washed five times in PBS containing 0.5% BSA
and incubated with a 1:200 dilution of Cy-3 conjugated AffiniPure donkey anti-mouse
IgG polyclonal antibody (715-165-150, Jackson ImmunoResearch Laboratories, West
Grove, PA) for an hour in the dark at room temperature. Following a total of 5 washes
with PBS containing 0.5% BSA, cells were incubated with 4’,6-diamidino-2phenylindole (DAPI) for 5 minutes in the dark at room temperature, to counterstain cell
nuclei. Coverslips were washed 3 times with PBS and mounted using VECTASHIELD
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antifade mounting medium (Vector Laboratories, Burlingame, CA). Cells were imaged
using an EVOS® FL (Life Technologies, Carlsbad, CA) at 200X magnification using
fluorescence from an RFP cube to visualize αSMA and a DAPI cube to visualize DAPI.
Coverslips with primary antibody alone or secondary antibody alone served as negative
controls.
RNA-Sequencing and Data Analysis
LX-2 cells (2x104 cells) were treated as described above. After 6 days, cells were
collected and shipped on dry ice to Novogene Corporation Inc. (Sacramento, CA), where
mRNA extraction, eukaryotic transcriptome library preparation (PCR-based), and
sequencing were performed. Briefly, mRNA was isolated using poly-T oligo-attached
magnetic beads. mRNA quality was determined using an RNA Nano 6000 assay kit for
the Bioanalyzer 2100 system (Agilent Technologies, CA, USA); only samples with an
RNA integrity number (RIN) >6.8 were used for library preparation. The libraries were
prepared using NEBNext® Ultra™ RNA Library Prep Kit for Illumina (Biolabs, Ipswich,
MA), and quality was determined by Qubit2.0 and Bioanalyzer 2100. Libraries were
sequenced on an Illumina Nova 6000 platform, and 150 bp paired-end reads were
generated with a read depth of ~20M per sample.
RNA-sequencing (RNA-seq) data analysis was performed in house. Raw data
were analyzed for per base sequence quality (>30), per sequence GC content, and adapter
(universal Illumina adapter) removal using FASTQC v0.11.9. The sequencing reads were
mapped to the human reference genome (GRCh38 release 99) using HISAT2 v2.1.0
(Kim, Langmead and Salzberg, 2015). Aligned reads were counted using HTSeq v0.11.3
(Anders, Pyl and Huber, 2015), and the counts were then analyzed for differential gene
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expression using median-ratio-normalization (Maza et al., 2013) with Deseq2 v1.22.2
(Love, Huber and Anders, 2014). Fold-changes were calculated by comparing counts in
all the treatments relative to CTRLs. Genes with an adjusted p-value < 0.05 were
considered differentially expressed. Enrichment analysis of differentially expressed genes
(DEGs) was performed in Cytoscape v3.7.0 using the ClueGo v2.5.1 visualization tool.
Measurement of mRNA Expression by Quantitative Real-Time PCR (qRT-PCR)
LX-2 cells were treated as described. mRNA was collected using the E.Z.N.A.®
Total RNA Kit (Omega Bio-Tek, Norcross, GA). RNA purity was assessed using a
Nanodrop 2000c (Thermo Scientific, Waltham, MA), and 500 μg of mRNA was reverse
transcribed using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific, Waltham, MA). Gene-specific primers (Table 1) were purchased from
Invitrogen (Carlsbad, CA) and used to amplify cDNA using FastStart Essential DNA
Green Master reaction mix (Roche, Indianapolis, IN) and a LightCycler® 96
Thermocycler (Roche, Indianapolis, IN). Samples were run in duplicate, and 3 samples
were used in each treatment group. Gene expression was normalized to β-ACTIN, and the
relative expression was estimated using the ΔΔCq method (Livak and Schmittgen, 2001).
mRNA levels are expressed as fold-change (mean ± SEM) relative to untreated, wildtype
LX-2 cells that were collected on day 0.
Statistical Analysis
Statistical significance was determined using a two-way ANOVA with Bonferroni
testing (p < 0.05) using GraphPad Prism 8.01 software (GraphPad Software, La Jolla,
CA). Unless otherwise noted, data represent mean ± SEM. Means that do not share a
letter are significantly different from each other (p < 0.05).
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Table 3.1
Gene
β-ACTIN
ACTA2
CCDN1
CDKN1A
CDKN1B
COL1A1
COL3A1
CYP1A1
CYP1B1
IL1B
CCL2
PDGFRB
TIMP1
TIMP2

Primer Sequences
Primer Sequence (5'to 3')
GAT GAG ATT GGC ATG
GAG AAG TGG GGT GGC
TCT GGA GAT GGT GTC
AAT AGC CAC GCT CAG
ATC AAG TGT GAC CCG
CTT GGG GTC CAT GTT
CTG CCG AAG TCA GTT
CAT GGC GCC TCC TCT
GCT AAC TCT GAG GAC
TGT TTT GAG TAG AAG
GGA ATG AAG GGA CAC
AGT AGC ACC ATC ATT
TCT GAG GAC CAG TAG
AAT CAA TGC CCC AGT
GAA TGA GAA GTT CTA
CAA GAC GAT GTT AAT
CAC TGC CAA CAC CTC
CAA GGA GCT CCA TGG
TCG CCA GTG AAA TGA
TGG AAG GAG CAC TTC
AAT CAA TGC CCC AGT
GGG TCA GCA CAG ATC
GGA GAG GGC AGT AAG
GAA GCC GCA TGG TGT
CTG TTG TTG CTG TGG
CGC TGG TAT AAG GTG
GAC GGC AAG ATG CAC
GAG ATG TAG CAC GGG

GCT
TT
ACC
TCA
GAC
CTG
CCT
G
ACG
AAT
AGA
TCC
GGC
CAC
CAG
GAT
TGT
ACT
TGG
ATC
CAC
TCC
GAG
CCT
CTG
GTC
ATC
ATC

Temp.(℃)
51

TT
CAC AAT
GG
TG
CT
TGT TGA

61

CAT
CGT
GGT
ACG
ATG
CT

52
CGG
T
A
ATT

52
54

52
67
43

CTT
CT
CT
TGT T
CT
TT
GA
TG
ATA G
TGG
AC
ATG G

57
53
54
54
58
63
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Results
Generation and Validation of AhR-Knockout in LX-2 Cells
To inhibit AhR activity in LX-2 cells, a CRISPR associated endonuclease (Cas9
protein) was delivered using three different guide RNAs (gRNAs) designed to produce
site-specific editing in exon 2 (Figure 3.1A). Transfection of LX-2 cells with RNPs that
contained either gRNA-1 or gRNA-3 produced low CRISPR/Cas9-mediated editing
efficiency compared to RNPs containing gRNA for RELA (Figure 3.1B). In contrast, the
delivery of RNPs containing gRNA-2 produced about twice as many mutations compared
to gRNA-RELA. About 33% of these mutations were indels, and 30% were frameshift
mutations. Sequence analysis of clones transfected with gRNA-2 led to the selection of
one clone (clone-2) that contained a 14-nucleotide deletion and demonstrated 98%
editing efficiency (data not shown). AhR activity was subsequently measured based on
the TCDD-induced expression of a gene set known to be regulated by AhR activation:
CYP1A1 (which encodes cytochrome P450 1A1) (Figure 3.1C) and CYP1B1 (which
encodes cytochrome P450 1B1) (Figure 3.1D). TCDD treatment induced expression of
both genes to varying extents in wildtype LX-2 cells but failed to do so in clone-2 cells.
Therefore, cells from clone-2 were selected for use in subsequent experiments and given
the designation "AhR-KO" LX-2 cells.
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Figure 3.1

Generation and Validation of AhR-Knockout LX-2 cells Using
CRISPR/Cas9

(A) Representation of the gRNA target region in AhR exon-2 and the designed sequences
to edit the coding sequence on this exon. (B) Cleavage efficiency was determined using
the online Synthego ICE tool. The total editing frequency of each gRNA is indicated as
Insertion-deletion (Indel) percentage. (C and D) AhR-KO and wildtype LX-2 cells were
treated with DMSO or 10 nM TCDD for 24 hours. mRNA levels of AhR-modulated
genes, CYP1A1, and CYP1B1, are expressed as fold-change (mean ± SEM) relative to
DMSO-treated wildtype LX-2 cells. Three samples were used for each treatment group;
each sample was run in duplicate. Means that do not share a letter are significantly
different from each other (p < 0.05).

Assessing AhR Activity in Wildtype and AhR-KO LX-2 Cells
To confirm AhR activity in wildtype cells and AhR ablation in AhR-KO cells, we
measured the mRNA expression of CYP1A1 and CYP1B1, which are known AhRregulated genes. Treatment with TCDD and ITE significantly increased expression of

100
these genes in wildtype LX-2 cells but not in AhR-KO cells (Figure 3.2A and B). Gene
expression was significantly reduced in wild-type LX-2 cells treated with the AhR
antagonist, CH22319.
Proliferation Is Reduced in AhR-KO Cells
One of the characteristics of HSC activation is increased proliferation. We found
that the number of wild-type LX-2 cells increased throughout the 6-day culture period.
However, proliferation was markedly reduced in AhR-KO cells (Figure 3.3A-C). The
change in proliferation after DMSO, ITE, and CH223191 treatments was not significant
(Figure 3.3A-C). In the AhR-KO cells, no statistically significant changes in proliferation
were observed for untreated and treated cells (Figure 3.3A-C).
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Figure 3.2

Assessing AhR Activity in Wildtype and AhR-KO LX-2 Cells

Wildtype and AhR-KO LX-2 cells were treated for 6 days with 10 nM TCDD, 1 μM ITE,
or 1 μM CH223191. Graphs show the mean fold-change (mean ± SEM) in mRNA
expression relative to untreated, wildtype LX-2 cells collected on day 0 denoted as
control (CTRL) for CYP1A1 (A), and CYP1B1 (B) genes; fold-change of 1, indicated by
the red-dashed line. Three samples were used for each treatment group; each sample was
run in duplicate. Means that do not share a letter are significantly different from each
other (p < 0.05).

Proliferation was further analyzed at the transcriptional level by measuring
mRNA expression of several well-established proliferation markers. In untreated
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wildtype cells, the mRNA expression of CCND1 (cyclin D1) increased throughout the
culture period. Upon treatment with TCDD and ITE, the expression was significantly
higher. Treatment with the AhR inhibitor, CH223191, did not change expression of
CCND1 compared to TCDD and ITE treated cells. However, CCND1 mRNA expression
in AhR-KO cells failed to increase across all the treatments (Figure 3.4A). Negative
proliferation regulator p21 (encoded by CDKN1A) mRNA expression significantly
increased in AhR-KO cells in culture induced activation and upon treatment with TCDD
and ITE (Figure 3.4B) but failed to increase in wildtype cells across all the treatments.
Another negative regulator of proliferation, CDKN1B, which encodes p27Kip1, showed
the opposite effect, as mRNA expression significantly decreased in AhR-KO cells in
comparison with TCDD- and ITE-treated wildtype cells (Figure 3.4C). No overt
differences were observed for mRNA expression of PDGFRB, which encodes platelet
derived growth factor receptor-beta. PDGFRB is a receptor for PDGF, which is a potent
mitogen for HSCs (data not shown). Similarly, RNA-seq analysis revealed decreased
expression of several proliferation markers in AhR KO cells (Figure 3.5).
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Figure 3.3

Proliferation Is Reduced in AhR KO Cells.

(A-C) Wildtype and AhR-KO LX-2 cells were treated for 6 days with 10 nM TCDD, 1
μM ITE, or 1 μM CH223191. Viable cell number were counted daily using a
hemacytometer and trypan blue exclusion. Data represent the mean ±SEM. Three
samples were used for each treatment group and each experiment was performed twice.
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Figure 3.4

Expression of Cell Cycle Regulatory Genes Is Altered in AhR KO
Cells.

Graphs show the mean fold-change (mean ± SEM) in mRNA expression relative to the
wildtype control (CTRL) for cycle cycle regulatory genes CCND1 (A), CDKN1A (B),
and CDKN1B (C); fold-change of 1, indicated by the red-dashed line. Means that do not
share a letter are significantly different from each other (p < 0.05).
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Figure 3.5

Heatmap Showing Expression of Cell Cycle Regulatory Genes in
Treated Wildtype and AhR-KO Clls

RNA-seq was used to assess expression of cell cycle regulatory genes. Gene expression
for all treatment groups was normalized to wildtype CTRL. Blue tiles indicate repression,
and red tiles indicate induction of gene expressions. Relative transcript abundance depicts
the mean of the normalized transcript counts of all samples for individual genes,
normalizing for sequencing depth. Green tiles indicate a high (>1000) relative transcript
abundance and white tiles indicate a low (<10) relative transcript abundance. Letters on
top represents the following: C = CTRL; D = DMSO T = TCDD, I = ITE, C =
CH223191.

AhR Removal Altered the Expression of Inflammatory Cell Infiltration Markers and
Genes Associated with Nuclear Receptors.
To assess the role AhR signaling plays in mediating cytokine production, we
measured the mRNA levels of IL1B and CCL2. In wildtype cells, TCDD and ITE
increased expression of both genes, and DMSO treatment also increased gene expression
compared to untreated cells, albeit to a lesser extent than ITE and TCDD treatments.
Unexpectedly, IL1B mRNA expression was severely repressed in AhR-KO cells across
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all treatments (Figure 3.6A). Similarly, mRNA expression of CCL2 was repressed in
AhR-KO cells compared to respective treatments in wildtype cells (Figure 3.6B). HSCs
also express diverse groups of nuclear transcription factor receptors such as liver X
receptor (encoded by NR1H3), farnesoid X receptor (FXR; encoded by NR1H4), PPARγ
(encoded by PPARG), PPARδ (encoded by PPARD), vitamin D receptor (encoded by
VDR), REVERBα (encoded by NR1D1) and nuclear receptor subfamily 4 group A
member 1 (encoded by NR4A1). NR1H3 and VDR expression showed no changed across
all treatments within the wildtype and AhR-KO cells. NR1H4, NR4A1, and PPARG
expression increased following AhR ablation in all treatments. In contrast, PPARD
expression decreased after AhR ablation regardless of treatment (Figure 3.6C).
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Figure 3.6

Cytokine and Nuclear Receptor Gene Expression is Modulated in
AhR-KO Cells

Graphs show the mean fold-change (mean ± SEM) in mRNA expression relative to the
wildtype control (CTRL) for IL1B (A) and CCL2 (A) genes; fold-change of 1, indicated
by the red-dashed line. Three samples were used for each treatment group; each sample
was run in duplicate. Means that do not share a letter are significantly different from each
other (p < 0.05). (C) RNA-seq was used to assess expression of nuclear receptor-related
genes. Gene expression for all treatment groups was normalized to wildtype CTRL. Blue
tiles indicate repression, and red tiles indicate induction of gene expressions. Relative
transcript abundance depicts the mean of the normalized transcript counts of all samples
for individual genes, normalizing for sequencing depth. Green tiles indicate a high
(>1000) relative transcript abundance, and white tiles indicate a low (<10) relative
transcript abundance. Letters on top represent the following: C = CTRL; D = DMSO T =
TCDD, I = ITE, C = CH223191.
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Knockout of AhR Increased LX-2 Cell Activation
To test whether AhR promotes HSC activation, we measured the protein levels of
the HSC activation marker, αSMA, in wildtype and AhR-KO LX-2 cells.
Immunofluorescence revealed that αSMA levels increased in AhR-KO cells (Figure
3.7A). Quantification of αSMA staining revealed that TCDD and ITE treatments
decreased the expression of αSMA levels in comparison to untreated and DMSO treated
wildtype LX-2 cells. The αSMA levels were not affected by CH223191 treatment. In the
AhR-KO cells, αSMA levels increased in comparison to respective treatments in
wildtypes (Figure 3.7B). The mRNA expression of ACTA2 (which encodes αSMA) and
COL3A1 (which encodes collagen type III, alpha 1) showed a similar trend of gene
induction in AhR-KO cells compared to wildtype cells (Figure 3.8A and B). However, no
changes in ACTA2 expression were detected in wildtype cells treated with TCDD and
ITE. A similar trend was observed for COL3A1 mRNA expression, as expression
increased in AhR-KO cells regardless of treatment. Expression of COL1A1, which
encodes collagen type I, and TIMP1, which encodes tissue inhibitors of
metalloproteinases 1, was slightly, but not significantly, diminished in AhR-KO cells
(Figure 3.8C and D). RNA-seq analysis revealed that COL3A1, TGFB2, IGFBP3, FN1,
PDGFRB, EDN1, and TGFA were induced across all treatments in AhR-KO cells. In
contrast, expression of COL1A1, LOX, TGFβ1, PDGA, PDGFB, and PDGFC were all
repressed across in AhR-KO cells regardless of treatment (Figure 3.8E).
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Figure 3.7

Increased αSMA Expression in AhR-KO LX-2 Cells

(A) Wildtype and AhR-KO LX-2 cells were treated with 10 nM TCDD or 1μM ITE or 1
μM CH223191 or equivalent DMSO (0.1% vol/vol) or left untreated altogether. αSMA
expression was measured using fluorescence microscopy (anti-αSMA, red; DAPI, blue).
Scale bar = 100 μm. (B) The pixel content of the red regions was quantified in five
separate fields per sample and expressed as a percentage of the total number of pixels.
Means that do not share a letter are significantly different from each other (p < 0.05).
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Figure 3.8

HSC Activation Markers in Wildtype and AhR-KO LX-2 Cells

Graphs show the mean fold-change (mean ± SEM) in mRNA expression relative to the
wildtype control (CTRL) for HSC activation marker genes ACTA2 (A), COL3A1 (B),
COL1A1 (C), and TIMP1 (D); fold-change of 1, indicated by the red-dashed line. Three
samples were used for each treatment group; each sample was run in duplicate. Means
that do not share a letter are significantly different from each other (p < 0.05). (E) RNAseq was used to assess expression of HSC activation-related genes. Gene expression for
all treatment groups was normalized to wildtype CTRL. Blue tiles indicate repression,
and red tiles indicate induction of gene expressions. Relative transcript abundance depicts
the mean of the normalized transcript counts of all samples for individual genes,
normalizing for sequencing depth. Green tiles indicate a high (>1000) relative transcript
abundance, and white tiles indicate a low (<10) relative transcript abundance. Letters on
top represent the following: C = CTRL; D = DMSO T = TCDD, I = ITE, C = CH223191.
Expression of Extracellular Matrix Remodeling Genes Is Modulated in AhR-KO LX-2
Cells
TIMP2 expression increased in wildtype cells and AhR-KO cells in all treatment
groups (Figure 3.9). Expression of fibrillar collagen genes COL1A1, COL3A1, and
COL4A5 was minimally impacted in wild-type cells, whereas COL6A3, a microfibril-
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forming collagen, was markedly repressed (Figure 3.). Gene expression for COL3A1, and
COL4A5 showed moderate induction across all treatments in AhR-KO cells, while
COL6A2 and COL6A3 showed robust repression. No treatment in wildtype cells elicited
gene expression changes for the gelatinase MMP2, which was repressed in AhR-KO cells
regardless of treatment. The scarcely expressed MMP3, which encodes the ECM
remodeling protein stromolysin-1, showed moderate-to-high gene induction across all
treatments in both wildtype and AhR-KO cells. Similarly, expression of MMP9, which
encodes a gelatinase, was reduced in all treatment groups regardless of AhR expression.
The mRNA expression of PLAT (tPA), the tissue-type plasminogen activator, was
slightly increased in wildtype cells following TCDD and ITE treatments but was
repressed in AhR-KO cells treated with DMSO, TCDD, or ITE. The mRNA levels of
SERPINE1 (PAI-1), a tPA inhibitor, and SERPINH1, a collagen synthesis chaperone,
showed moderate repression in wildtype cells upon TCDD and ITE treatments but were
moderately increased in AhR-KO cells upon DMSO, TCDD, and ITE treatment.
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Figure 3.9

Expression of ECM Remodeling Genes in Wildtype and AhR-KO
LX-2 Cells

Graphs show the mean fold-change (mean ± SEM) in TIMP-2 mRNA expression relative
to the wildtype control (CTRL); fold-change of 1, indicated by the red-dashed line. Three
samples were used for each treatment group; each sample was run in duplicate. Means
that do not share a letter are significantly different from each other (p < 0.05).
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Figure 3.10

ECM Remodeling Markers in Wildtype and AhR-KO LX-2 Cells

Gene expression for all treatment groups was normalized to wildtype CTRL. Blue tiles
indicate repression, and red tiles indicate induction of gene expressions. Relative
transcript abundance depicts the mean of the normalized transcript counts of all samples
for individual genes, normalizing for sequencing depth. Green tiles indicate a high
(>1000) relative transcript abundance, and white tiles indicate a low (<10) relative
transcript abundance. Letters on top represent the following: C = CTRL; D = DMSO T =
TCDD, I = ITE, C = CH223191.
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Discussion
The present study investigated the mechanistic role of AhR signaling in HSC
activation. Several studies have suggested both a pro-fibrotic and an anti-fibrotic role of
AhR signaling during HSC activation and the development of liver fibrosis. For instance,
our lab showed that TCDD increases HSC activation in mouse and in vitro models of
experimental liver fibrosis (Harvey et al., 2016; Lamb et al., 2016a). In contrast,
treatment with the endogenous AhR agonist, ITE, reduced HSC activation and liver
fibrosis in mice (Yan et al., 2019). These findings raise the intriguing possibility that
HSC activation could be therapeutically targeted by AhR ligands to mitigate progression
of liver fibrosis.
Results from this study indicate that removal of AhR signaling altogether
increased LX-2 cell activation, which supports the notion endogenous AhR activity could
repress HSC activation. Unexpectedly, LX-2 cell proliferation was diminished in the
absence of the AhR.
To our knowledge, this is the first report of a stable AhR knockout in LX-2 cells.
The AhR-KO cells were confirmed for single-clonal purity using the Inference of
CRISPR edits (ICE) tool (https://ice.synthego.com/#/). Approximately 98% of the
population from the selected clone was shown to be from a single cell (Supplementary
Fig. S1B). Further, AhR-knockout was confirmed by the significant reduction of mRNA
expression of CYP1A1 and CYP1B1, which are AhR-regulated genes known to be
induced upon TCDD treatment. Light-microscopic morphology of AhR-KO LX-2 cells
were similar to wildtype cells (data not shown). This cell line may prove useful for
advancing our knowledge of AhR biology in a pure population of HSCs in vitro.
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The conflicting pro- and anti-fibrotic roles of AhR signaling during HSC
activation and collagen deposition merit further investigation (Harvey et al., 2016; Lamb
et al., 2016a; Yan et al., 2019). It is possible that conflicting results are due to cellspecific roles of AhR and the influence of injury and inflammation during HSC activation
during in vivo models. Our findings support the notion that AhR functionality is crucial
for repressing HSC activation, as evidenced by the increase in αSMA protein and mRNA
expression following AhR knockout. This observation corroborates another report in
which primary mouse cells isolated from HSC-specific AhR knockout mice showed
increased expression of activation markers (Yan et al., 2019). Interestingly, results from
this present study suggest that gene expression of some HSC activation markers increased
following AhR knockout, and while others decreased. This suggests that HSC activation
could occur through “tiered” activation, with some markers requiring additional stimuli
from secondary or tertiary signals, possibly from injury or inflammation.
We previously reported that TCDD treatment increased proliferation of cultured
LX-2 cells (Harvey et al., 2016). In contrast, primary mouse HSCs isolated from HSCspecific AhR knockout mice reportedly showed a significant increase in proliferation
after culture-induced activation for 48 hours, but wildtype primary mouse HSCs failed to
elicit a similar response (Yan et al., 2019). Overall, the role of AhR in regulating cell
proliferation is unclear. Interestingly, we observed a lag period of 48 hours before cells
commenced proliferation upon TCDD treatment (Harvey et al., 2016). Based on all these
data it can be speculated that the role of AhR on proliferation is time-dependent. Our data
indicate that AhR signaling is required for optimal LX-2 cell proliferation, which is
evident from the decrease in proliferation in AhR-KO cells. Interestingly, in wildtype
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cells, TCDD treatment increased proliferation, whereas ITE treatment did not. It is
possible that exogenous and endogenous ligands activate unique signaling cascades to
produce these disparate effects.
HSC activation is characterized by increased proliferation and increased
expression of genes involved in fibrogenesis. Recent reports suggest that AhR-mediated
inhibition of HSC activation occurs independently of proliferation (Yan et al., 2019).
This is corroborated by our data, in which removal of the AhR appeared to decrease cell
proliferation but not activation. It is possible that endogenous AhR activity positively
regulates cell cycle progression through expression of CCND1 and CDKN1A, which
positively and negatively regulate passage through the G1/S checkpoint of the cell cycle,
respectively. CDKN1A encodes the Cip/Kip inhibitor, p21Cip1, the expression of which
would be expected to halt proliferation. Endogenous AhR activation may be preventing
the upregulation of CDKN1A mRNA. A decrease in CDKN1B mRNA expression in
AhR-KO without affecting the proliferation suggests that the reduction of proliferation in
AhR-KO cells is independent of CDKN1B and dependent on CDKN1A.
It is known that activated HSCs produce diverse mitogenic and fibrogenic
cytokines and cytokine receptors for autocrine and paracrine signaling. On one hand, our
data demonstrate that AhR knockout significantly decreased CCL2 mRNA expression,
which functions as an autocrine stimulus, as well as a monocyte and lymphocyte
chemoattractant (Marra et al., 1993; Marra et al., 1999). It is possible that CCL2 had a
limited role in our model system towards HSC activation. Another important cytokine
mediator, IL-1B, was recently shown to reduce αSMA expression in human HSCs. Data
from our study suggest that IL1B expression is severely repressed in AhR-KO cells. This
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led us to speculate that one of the mechanisms by which endogenous AhR signaling
prevents HSC activation is by inducing IL1B expression. On the other hand, expression
of the transcription factor receptor NR1H4, which is known to modulate HSC activation
by inhibiting glucose and lipid metabolism, was significantly increased upon AhR
knockout (Kong et al., 2009). In contrast, expression of PPARG, which encodes another
nuclear receptor known to negatively modulate HSC activation (Hazra et al., 2004), was
significantly decreased in AhR-KO LX-2 cells. These positive and negative regulatory
events could be the direct result of AhR knockdown, or they could reflect secondary
effects elicited to compensate for the knockdown.
Our data showed that TCDD and ITE altered the expression of only a subset of
genes involved in ECM remodeling, which implies that the induction of some of these
genes may require additional signaling from injury and/or inflammation. For example,
TGFB1 and COL1A1 gene expression were not affected by TCDD and ITE treatments.
Previous studies have shown that TCDD treatment modulates ECM remodeling genes in
vivo (Lamb et al., 2016b). Interestingly, AhR removal had minimal effects on the
expression of these two genes, implying that endogenous AhR signaling play a minimal
role in regulating gene expression for TGFB1 and COL1A1. It is possible that AhR is
required for the expression of MMP2, MMP9, and MMP14 genes. Interestingly, MMP3
gene expression increased upon AhR activation and further increased upon AhR removal.
For example, knocking out the AhR from LX-2 cells slightly induced SERPINE1 (PAI-1)
and SERPINH1 expression and decreased PLAT (tPA). Hence it is possible that AhR
removal reduces levels of plasmin, which is known to convert pro-MMPs into
enzymatically active MMPs. It is possible that the AhR is regulating the expression of
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certain genes directly. Further investigation will be needed to assess how endogenous
AhR activity impacts MMP expression. This could occur through a direct effect or by
indirectly modulating expression of MMPs, TIMPs, and other regulators in the plasmin
system.
In conclusion, we established a novel AhR-KO LX-2 cell line to study the
endogenous and exogenous role of AhR activation. This enabled us to study the role of
AhR signaling in HSC activation without the involvement of hepatic inflammation and
injury, which are typically present in in vivo models of experimental liver fibrosis. Our
findings provide further evidence to support a role for endogenous AhR activity in
repressing HSC activation. In the absence of endogenous AhR activity, LX-2 cell
proliferation decreased, while endpoints of activation increased. Future studies should
include an examination of the distinct signaling pathways used during HSC proliferation
and activation to identify unique targets that could potentially be modulated by
therapeutic AhR ligands to reduce or reverse HSC activation and curtail liver fibrosis.
Supplementary Material and Methods
Generation of AhR-KO LX-2 cells
Sanger-Sequencing
The region around exon-2 of the AhR gene was amplified using the primers listed
in Supplementary Table S1. The PCR protocol consisted of a 10-minute enzyme
activation at 95°C, followed by 40 cycles (30 seconds at 95°C, 30 seconds at the
annealing temperature, and 30 seconds at 72 C), and a final extension for 7 minutes at
72°C. Cleaning and sequencing of the PCR product was carried out at the Molecular
Research Core Facility (Idaho State University, Pocatello, ID). Briefly, cleaned PCR
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products were quantified using the Qubit 2.0 Fluorometer and prepared for sequencing
using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Cat.
#4337455) and sequenced on an Applied Biosystems 3130xl Genetic Analyzer with a
3130xl⁄3100 Genetic Analyzer 16-Capillary Array, 50 cm. Sequencing base calls were
determined by Sequence Analysis Software v6.0 using the default analysis settings.
Single Clone Isolation of AhR Mutant Clones
After nucleofection with the gRNA-2 RNP, LX-2 cells were plated on a 10-cm
culture dish (1000 cells/dish) and incubated for 10 days. On day 11, individual clones
were collected with sterile pipet tips and transferred to 96-well tissue-culture plates.
Thirty-four clones were selected this way and expanded in culture for several days. DNA
was then isolated from these clones, and the region around exon-2 was amplified. The
quality of the PCR product was assessed by resolving it on a 2% agarose gel and
visualizing bands with ethidium bromide (Supplementary Figure 3.S1A). The PCR
products were then analyzed by Sanger sequencing using the protocol described above.
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Supplementary Data

Supplementary Figure 3.1 Generation of AhR-KO LX-2 Cells
The percentage of insertion-deletion (INDEL) mutations in clone-2 was calculated using
the Sanger ICE online tool. The X-axis represents the number of base pairs of addition or
deletion. The Y-axis represents the percentage of INDEL mixtures. The editing efficiency
refers to the percentage of INDEL mixtures.
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Supplementary Figure 3.2 Analysis of Gene Expression Variances Using Principal
Component Analysis (PCA).
PCA analysis of gene expression across all treatments in wildtype and AhR-KO LX-2
cells. The components PC1 and PC2 define the x- and y-axis, respectively. The distance
between any two points represents the variance in gene expression between them. (A)
PCA plot was generated using the rlog transformation (rld) function of normalized count
data. (B) PCA plot was generated using the variance stabilizing transformation (vst)
function of normalized count data.
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Supplementary Figure 3.3 'MA Plots' for Differentially Expressed Genes
(A-E) 'MA plots' for differentially expressed genes (red) enriched for the defined
comparisons shown at the top of each figure.
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CHAPTER FOUR: SUMMARY AND FUTURE DIRECTIONS
Summary
Several studies implicate a role for AhR signaling in the regulation of HSC
activation and the development of liver fibrosis. However, little is known about AhR
activation in this relatively small population of liver cells. Furthermore, in the absence of
liver injury or inflammation, HSCs typically exist in a quiescent form. It is quite possible
that short-term transient activation of the AhR with a potent agonist such as TCDD fails
to elicit remarkable changes in quiescent HSCs. This could explain why previous studies
failed to find any significant, reproducible effects of AhR activation on these cells. Given
the involvement of multiple liver cell populations in the development of fibrosis, the
endogenous role of the AhR may be unique among individual cell populations.
The first goal of this dissertation was to determine how AhR signaling in
hepatocytes and in HSCs contributed to HSC activation and fibrogenesis in mice treated
chronically with TCDD. One of the challenges of in vivo studies is presence of
confounding variables, such as injury and inflammation, which also facilitate HSC
activation. This makes it difficult to distinguish between AhR-mediated events in the
HSCs and those events in hepatocytes and other cells, such as macrophages. The second
goal of this dissertation was to determine the direct impact of AhR functionality during
HSC activation, in the absence of secondary effects. To accomplish this AhR signaling
was evaluated in LX-2 cells lacking AhR functionality. Furthermore, transcriptome

130
analysis was carried out for liver tissues from mice and LX-2 cells to identify AhRmodulated transcriptional changes.
Results from Chapter 2 indicate that TCDD increases HSC activation through a
mechanism that requires AhR signaling in hepatocytes. Moreover, this possibly occurs
through a steatosis-dependent mechanism that is independent of inflammation. Although
less likely, we cannot completely exclude the possibility that TCDD directly activates
HSCs, but maximal HSC activation in TCDD-treated mice is not achieved through AhR
signaling in HSCs alone. We also found that AhR signaling in hepatocytes and HSCs was
not an absolute requirement for hepatic inflammation.
Data presented in Chapter 3 describe the successful creation of the AhR-KO LX-2
cells, which were then used to investigate the impact of endogenous and exogenous AhR
activity on HSC activation. Results support the notion that the AhR functions as an
endogenous repressor of HSC activation. Furthermore, we found that removal of the AhR
decreased LX-2 cell proliferation. It is possible that the reduction of proliferation in AhRdeficient cells occurs through the upregulation of p21Cip1, which is a negative regulator
of cell cycle progression at the G1/S phase checkpoint. This AhR-deficient cell line could
be used to investigate how alternative AhR ligands might be used therapeutically to
modulate HSC proliferation and activation, both of which could influence the
development and progression of liver disease.
Future Directions
The complex role AhR activity in liver fibrosis highlights the intriguing
possibility that the AhR could play diverse, cell-specific roles during liver health and
disease. A recent study reported that chronic exposure to TCDD modulated hepatocyte
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gene expression to essentially reorganize glycogen, ascorbic acid, and amino acid
metabolism in support of ECM remodeling (Nault et al., 2016). However, the
contribution of AhR to these individual metabolic pathways is largely unknown. For
instance, transcriptome analysis of hepatic tissue from mice with AhR-deficient
hepatocytes identified 570 genes that were differentially expressed in response to TCDD.
In comparison, only 21 genes were differentially expressed in the liver of TCDD-treated
mice with AhR-deficient HSCs, compared to their wild-type counterparts. It could be
argued that, since hepatocytes make up about 80% of the liver cell population, and
because my research shows that TCDD directly targets hepatocytes, one would expect to
see a large number of differentially expressed genes. However, very few genes were
found to be sigificantly repressed in both hepatocyte- and HSC-specific knockout mice.
Hence, specific genes and pathways may be exclusively dependent on hepatocyte- and
HSC-specific AhR signaling. A logical next step would be to validate these genes and
pathways to understand their contributions to HSC activation and liver fibrosis.
Eventually, this might shed light on how AhR signaling impacts liver fibrosis.
The physiological role of endogenous AhR activity likely depends on the tissue of
consideration, and this is an emerging area of research. In LX-2 cells, AhR activation by
TCDD or ITE produced 117 and 174 differentially expressed genes, respectively, when
compared to untreated cells. It can be speculated that the difference in gene expression
for 57 genes is probably due to endogenous AhR signaling, as ITE is a potent endogenous
ligand of the AhR. It would be logical to further assess the molecular pathways that these
57 genes regulate to understand endogenous ligand-specific AhR activation. Furthermore,
the transcriptome analysis of AhR-knockout LX-2 cells revealed 9789 differentially
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expressed genes compared to wildtype LX-2 cells. This significant number raises the
possibility of the interplay and crosstalk between the AhR and a wide variety of pathways
and genes. Future studies could validate changes in enriched pathways and shed light on
divergent and convergent AhR signaling pathways. Accomplishing these tasks will
potentially provide a basis for additional studies to identify and test novel AhR ligands
for therapeutic use as modulators of HSC activation.
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APPENDIX A
Generation of Mice With AhR-Deficient Hepatocytes and AhR-Deficient Hepatic
Stellate Cells
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Introduction
Experiments in this dissertation rely on the generation of mice with a liver cellspecific deletion of the aryl hydrocarbon receptor (AhR). To this end, a Cre-Lox system
was used to selectively remove the AhR from either hepatocytes or hepatic stellate cells
(HSCs).
Mice expressing floxed AhR gene (Ahrtm3.1Bra/J, The Jackson Laboratory, Bar
Harbor, ME), referred to as AhRfl/fl, were crossbred with each other to produce male
AhRfl/fl. For hepatocyte-specific AhR knockout mice, referred to as AhRΔHep mice, female
albumin-Cre recombinase (Alb-Cre) transgenic mice (B6N.Cg-Speer6-ps1Tg(Alb-cre)21Mgn/J,
The Jackson Laboratory) were crossbred with male AhRfl/fl mice to produce AhRfl;Alb-cre
females. AhRfl;Alb-cre females were then crossbred with AhRfl/fl males to generate mice
homozygous for floxed AhR and hemizygous for Alb-Cre. Mice homozygous for floxed
AhR were used as controls and referred to as AhRfl/fl . Similarly, for HSC-specific AhR
knockout mice, referred to as AhRΔHSC mice, female glial fibrillary acidic protein
promoter-Cre recombinase (GFAP-Cre) transgenic mice (FVB-Tg(GFAP-cre)25Mes/J,
The Jackson Laboratory, Bar Harbor, ME) were crossbred with male AhRfl/fl mice to
produce AhRfl; GFAP-cre females. AhRfl; GFAP-cre females were crossbred with AhRfl/fl males
to generate mice with homozygous for floxed AhR and heterozygous for GFAP-Cre.
Several reports suggest that GFAP-Cre specifically targets HSCs (Kocabayoglu et al.,
2016; Ceni et al., 2017; Alsamman et al., 2018). mice were used as controls. All
individuals were generated on a C57BL/6 background.
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AhR Gene Alleles
Mice express one of four phenotypic alleles of the AhR gene: Ahb-1, Ahb-2, Ahb-3,
and Ahd (Poland and Glover, 1990). The Ahb-1 allele encodes a protein of 805 amino
acids (~95kDa), the Ahd and Ahb-2 alleles encode a protein of 848 amino acids
(~104kDa), and the Ahb-3 allele encodes a protein of 883 amino acids (~105kDa) (Poland,
Glover and Taylor, 1987; Poland and Glover, 1990). These allelic variants of the AhR
express different binding affinities for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)
(Chang and Puga, 1998). Ahb-1, Ahb-2, and Ahb-3 alleles encode an AhR protein with high
ligand-binding affinity, whereas the Ahd allele encodes a protein with low-binding
affinity. These four alleles are distributed across strains of laboratory mice such that some
strains of mice are sensitive to TCDD toxicity, whereas other strains are highly resistant.
For example, C57Bl/6 mice carry the Ahb-1 allele that encodes an AhR that binds to
TCDD with high affinity. As a result, these mice are sensitive to the toxic effects of
TCDD, with an LD50 of ~ 114 µg/kg (Poland, Palen and Glover, 1994). Most studies of
TCDD toxicity and AhR biology have been conducted in C57Bl/6 mice. In contrast,
strains that express the d allele of the AhR, such as FVB-129 are highly resistant to
TCDD toxicity, requiring doses of TCDD that are 10-20 times higher to produce lethality
(LD50 of ~ 536 µg/kg) (Swanson and Bradfield, 1993). 129SvJ ES mice are widely used
in the production of targeted mutations due to the availability of multiple embryonic stem
cell lines derived from them. In fact, the AhRfl/fl used for initial breeding was on a 129SvJ
ES background.
The change in affinity among alleles is attributed to structural changes associated
with amino acid mutations. A study conducted by overlapping five fragments of AhR
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coding sequence and PCR sequencing ten, 10-nucleotide differences between Ahb-1 and
Ahd alleles. Five of the differences were found to be silent. Among the remaining five,
four of them replaced the leucine residue in Ahb-1 with a proline residue in Ahd, which
results in a potential break in the alpha-helix near the Q-rich region of the AhR. The one
remaining change replaces the termination codon in Ahb-1 with an arginine residue in Ahd
at position 3330. This extends translation by 43 amino acids, which eventually results in a
change in size from 95 kDa to 105 kDa (Chang et al., 1993).
Because we used SV129 mice (Ahd allele) and crossed them with C57Bl/6 mice
(b allele), it was important to identify which AhR allele was expressed in the offspring, as
this would be the main factor in selecting the dose of TCDD used for our experiments.
Materials and Methods
DNA Isolation
Tissue was collected by ear punch from founder mice and offspring. DNA was
extracted using Extracta™ DNA Prep for PCR (Quanta Biosciences, Beverly MA)
according to the manufacturer’s protocol.
Primer Design
Primers were designed to flank exon 11 of the AhR, which has 12 nucleotides;
the point mutation was expected to occur at the 10th position. Forward primer
(CGAAAGACTTAGCCATGAGC) and reverse primer
(GAAGTTACTGAGCAGGGAACC) were designed to anneal to DNA 123 and 292
nucleotides from the expected point mutation.
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PCR Amplification
Genomic DNA (100 ng) was amplified with the primers shown above using
GoTaq G2 colorless master mix (Promega, Madison, WI). Samples were run in duplicate.
The master mix containing genomic DNA and primers was preincubated at 95° C for 10
minutes followed by 40 cycles at the following protocol: denaturation at 95° C for 30
seconds, annealing at 57° C for 30 seconds, amplification at 72° C for 30 seconds for 40
cycles. After a final extension at 72° C for 10 minutes, PCR products were separated on a
2% agarose gel, and bands were visualized under UV light using ChemiDoc imaging
systems (Biorad, Hercules, CA). The expected amplicon size was 516 base pairs.
Sanger Sequencing
Sanger sequencing was carried out at Idaho State University. In brief, the
amplified products were cleaned using a PCR Cleanup kit (Thermo Scientific, Waltham,
CA) and prepared for sequencing using the BigDye® Terminator v3.1 Cycle sequencing
kit (Applied Biosystems, Foster City, CA). Sequencing was performed on Applied
Biosystems 3130xl Genetic Analyzer with a 3130xl⁄3100 Genetic Analyzer 16-Capillary
Array, 50 cm; sequencing base calls were determined by sequence analysis software v6.0
using the default analysis settings.
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Results
AhRfl/fl, AhRΔHep, and AhRΔHSC Mice Express the Ahd Allele
To determine which AhR allele was expressed in the cell-specific knockout mice,
we sequenced exon 11. The results in Figure A.1 show the sequencing data of exon 11 in
C57BL/6, AhRfl/fl, AhRΔHep, and AhRΔHSC mice. C57BL/6 was found to have thymine,
and AhRfl/fl, AhRΔHep, and AhRΔHSC mice were found to have cytosine, at position 3330.

Figure A.1

Sanger Sequence Analysis of Amplified PCR Products

The nucleotide sequence at position 3330 (indicated by the black arrow) indicates whether
the b or d AhR allele is expressd.
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Discussion
In this study, we determined which allele was present in the mice used for the
experiments described in Chapter 2. AhRfl/fl, AhRΔHep, and AhRΔHSC mice were all found
to have the ‘d’ allele, which encodes an AhR protein with relatively low ligand-binding
affinity. This is due to the fact that conditional AhRfl/fl mice were originally generated
from 129SvJ ES cells that carry the lower affinity Ahd (Walisser et al., 2005).
In Chapter 2, we used a 100-µg/kg dose of TCDD, which is 3-4 times higher than
25-30 µg/kg doses reportedly in other studies of TCDD-induced liver fibrosis in
C57BL/6 mice that carry the b allele (Pierre et al., 2014; Nault et al., 2016). Other
investigators have used the 100 ug/kg dose of TCDD to produce classic endpoints of
TCDD toxicity in mice carrying the d allele (Walisser et al., 2005). This dose was found
to induce hepatomegaly, mild elevation in serum ALT levels, and increased expression of
Cyp1a1. Furthermore, it did not produce any lethality. For this reason, we selected the
100 µg/kg dose of TCDD to use in the experiments described in Chapter 2.
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